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Chapter 1 Introduction and 
outline of the thesis
2Chapter 11
Indonesia is facing a rapidly growing HIV epidemic, which has been driven initially 
by injecting drug use among males in large parts of the country.1, 2 In recent 
times, heterosexual transmission has become the most common reported HIV 
transmission risk behaviour, rising from 37% to 71% within a decade.3 Although 
HIV seroprevalence rates among people who inject drugs (PWID) declined from 
52% to 36% between the years 2001 and 2011, it remains very high.3 Drug use 
is illegal in Indonesia which limits PWID access to the health care system and 
puts them at risk of being imprisoned. Substantial numbers of PWID go in and 
out of prison every year in Indonesia, making the interaction between prisons 
and the Indonesian society very large.4 Prison health is part of public health and 
prisons should be seen as part of the Indonesian society. If no appropriate action 
is taken, prison may become breeding places for communicable diseases, like HIV, 
hepatitis B (HBV) and hepatitis C (HCV).5, 6 Incarceration should therefore be used 
for the benefit of the prisoner’s health as well as for society,4 and this forms the 
basis of the present thesis focused on the Indonesian situation.
Globally, there are more than 10 million people imprisoned at any given time 
point and every year more than 30 million people spend time inside prisons.7 
General health, mental health and substance abuse problems often are more 
apparent in jails (where those arrested wait their trial) and in prisons compared 
to the general community.8-10 Communicable diseases are frequently transmitted 
among prisoners, and HIV, HBV, HCV and tuberculosis rates are much higher among 
them than in the general population, especially when drug use is common.5, 6, 10, 
11 Furthermore, overcrowding, poor hygienic conditions, poor knowledge of HIV 
and hepatitis transmission among inmates, and poor health facilities in prison 
make prisoners vulnerable to acquire and transmit HIV, HBV and HCV.4, 10, 12, 13 
Importantly, as an important risk factor for TB reactivation, HIV infection also 
fuels the spread of tuberculosis in the prison setting. 
A large proportion of Indonesian prisoners are active or occasional recreational 
drug users. Recent data show that drug related crimes contributed to 30% of total 
offences in Indonesian prison and 50% of those inmates being active injecting 
drug users.2 Many of them suffer from communicable diseases such as HIV, HBV, 
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HCV and TB. In Indonesian prison, HIV seroprevalence rates as high as 20% to 
50% has been reported in studies, although most surveys were small,14, 15 which is 
more than 30 times higher compared to the estimated HIV prevalence of 0.4% in 
the general community. Reliable data on HCV and HBV within Indonesian prison 
have been lacking so far.
Because of the concentration of infections, prisons may offer good opportunities 
for interventions to contain these infections. Unfortunately, such interventions 
inside prison are rarely implemented, not only in middle- and low-income countries 
but also in industrialized countries. Comprehensive prevention program should 
include: 1) HIV/Hepatitis education, 2) voluntary HIV/HCV testing and counseling, 
3) condom supply, 4) prevention of rape and sexual violence, 5) treatment of 
HIV-positive prisoners and 6) a needle exchange and methadone maintenance 
program.10, 16, 17 Such activities can be established if there is commitment from 
prison authorities, endorsement of services by prison staff and prisoners, and 
collaboration with health care providers outside the prison. It is important to focus 
on the prison population, as at risk populations outside the prison may be more 
difficult to access,10 while at risk inmates are easier to access and their treatment 
may be more cost-effective.18-20 However, budget restrains, lack of policies, stigma 
and logistic reasons are among the reasons that limit the implementation of 
programs to fight communicable diseases in prison settings.21, 22
In light of the likely burden of HIV and other infections in prison, and the 
opportunities of prisons as a place where HIV care, treatment and prevention 
could be addressed, we initiated several studies inside prison. As an initial step, 
the possibility of linking prison with other health institutions was evaluated. 
Afterwards, HIV, hepatitis B and C prevalence among unselected inmates was 
examined, and related to risk behaviour. Then, the impact of implementing care 
and treatment and prevention for HIV inside prison and the best approach to 
provide HIV testing inside prison were determined.
This thesis consists of studies in a referral narcotic prison in Bandung, West 
Java (Banceuy prison) and a female detention center in Jakarta (Pondok Bambu, 
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East Jakarta detention center). These studies were possible as Hasan Sadikin 
University Hospital and Banceuy prison have established a memorandum of 
understanding to prevent, control and treat HIV among PWID in West Java while 
Cipto Mangunkusumo University Hospital provides clinical mentoring for HIV 
related illness to the Pondok Bambu detention center for female prisoners in East 
Jakarta. 
Banceuy Narcotic Prison is the referral prison for drug related offences in West 
Java, admitting inmates sentenced for more than a year. Banceuy prison is 
overcrowded as more than 1000 inmates are usually incarcerated which is double 
its total capacity of only 500 inmates. In terms of medical service, Banceuy 
has an outpatient and 12-beds of inpatient facility, served by one general 
practitioner and two dentists for general care, and more specific tasks such as 
HIV and addiction care. Before the implementation of specific HIV interventions, 
Banceuy prison reported around 20% HIV prevalence among inmates. In 2006, 
as a result from the PRIOR program, Banceuy prison established a collaboration 
with Hasan Sadikin Hospital, referral hospital for West Java, to provide specialists 
consultation on a weekly basis. A year later, a large EC funded comprehensive 
and integrated program to prevent, control and treat HIV among PWID in West 
Java, named IMPACT was started, which facilitated the implementation of a series 
of interventions at Banceuy prison as well. Between the years 2007-2012,23 HIV 
education, screening of HIV status through voluntary counseling and testing (VCT) 
or provider initiated testing and counseling (PITC), provision of antiretroviral 
treatment for HIV-seropositive and monitoring treatment outcome became 
available at Banceuy prison. In addition, the implementation of methadone 
maintenance program at Banceuy prison was explored as well. In order to make 
interventions evidence based, a series of studies was performed at Banceuy 
prison, which are reported in this thesis.  
Pondok Bambu detention center, located in East Jakarta, is a place designed 
specifically for female inmates with a capacity for around 600 inmates. Most 
of the time, Pondok Bambu prison is however occupied with more than 1000 
females, 60% of these cases being drug related offences. There is little attention 
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for substance and alcohol among females is in most studies, and most studies 
among women in western societies focus on tobacco and alcohol.24 As such 
there is a need for more study on substance abuse in female prisoners, also in 
Asian settings, where the situation may be very different. This could help tailor 
prevention programs. 
Outline of the thesis
This thesis addresses several aspects related to HIV infection in prison in Indonesia. 
The first part explores the opportunity to link prison with other health institutions 
to provide comprehensive care for inmates for HIV and other diseases. In 
Chapter 2 we reviewed HIV prevention and care in prison and described initial 
experience of the first of such collaborative efforts in Indonesia. Prisons may fuel 
the HIV epidemic, but at the same time may provide an excellent opportunity 
for interventions. However, there are challenges to implement a comprehensive 
program to prevent, control and treat HIV, HBV and HCV inside Indonesian 
prisons. Furthermore, essential components and pre-conditions that need to be 
considered to maintain the sustainability of such program are discussed as well. 
These issues are addressed in Chapter 2
The second part includes studies on the prevalence of HIV and HBV, HCV infections 
inside prison, and on related risk behavior. In Chapter 3 we examined the 
magnitude of the problem related to the major blood borne infectious diseases 
inside Banceuy prison. In addition, as it is well known from literature that HIV, 
HBV and HCV are transmitted within prisons, we studied which factors underlie 
HIV transmission risk behavior inside the prison. More specific, we investigate the 
association of impulsivity and risky behaviors, also the association of impulsivity 
and the prevalence of HIV, HBV, HCV and syphilis (Chapter 4). The study was 
done in female prisoners, because drug use among females is recognized as an 
increasing problem in Indonesia and relatively few studies focus on females.  
The third part describes the implication of providing care and treatment for HIV, 
HBV, HCV infection inside prison, that Includes 1) HIV education, 2) voluntary 
HIV testing and counseling, 3) condom supply, 4) prevention of rape and sexual 
6Chapter 11
violence, 5) antiretroviral treatment for HIV-positive prisoners and a 6) methadone 
maintenance treatment (Chapter 5). The sustainability of a HIV prevention, 
control and care program inside prison is an important issue to be considered. 
Therefore, testing strategies in correctional settings exploring the feasibility, 
acceptance, yield, and cost-effectiveness were studied. We evaluated two HIV 
screening strategies in Banceuy narcotic prison in Indonesia: at first routine HIV 
screening was done during a period of 18 months after the policy was changed 
because of budgetary reasons to a targeted screening of inmates that reported 
injecting drug use. The change from routine to targeted screening in Banceuy 
prison allowed us to evaluate how this policy change affected HIV case detection 
rates, expenditures and access to treatment (Chapter 6). 
Finally, the main findings of this thesis, suggestions for further research and 
recommendations to improve policies to contain HIV, HBV, HCV and syphilis within 
prison in Indonesia are described in Chapter 7.
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Abstract
Around the world, HIV-prevalence rates among prisoners are high compared to the general 
population. This is due to overrepresentation of injecting drug users (IDUs) in prison and 
possible HIV-transmission inside prison. Limited health services in penitentiary institutes, 
stigma, policy issues, and budgetary constraints may hamper delivery of appropriate 
services for HIV in prison. Prisons may on the other hand enable the access to a high risk 
population for HIV-prevention and -care. IDUs are namely hard to reach outside prisons, 
while in prison targeted interventions for IDUs can be used repeatedly and economically. 
Also, harm reduction and HIV-treatment can be supervised and monitored carefully. 
This paper reviews HIV-prevention and care in prison, and describes the experience in one 
particular prison in West Java Indonesia. Based on the literature and local experience one 
can conclude that effective and widespread HIV-testing and treatment can be established 
in prisons if there is commitment from prison authorities, endorsement of services by 
prison staff and inmates, and collaboration with health care providers from outside prison. 
Essential components of HIV-services in prison include appropriate health care services, 
a suitable environment for HIV-counseling and -testing and tailored services for injecting 
drug use. By partner counseling and linking HIV-services in prison with continued care 
afterwards, prisons may contribute significantly to HIV-control in the general population, 
especially in settings where HIV is often due to injecting drug use.
Key words: Indonesian prisons, HIV, injecting drug users
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Introduction
Indonesia has one of the most rapidly growing HIV-epidemics in Asia, which is 
in most parts of the country largely fuelled by injecting drug use (IDU).1,2 Drug 
use is illegal and imprisonment is therefore a common and recurrent event for 
most injecting drug users (IDUs). Reports from outside Indonesia indicate that the 
risk of being infected in prison, specifically through the sharing of contaminated 
injecting equipment, is high.3 Similar to many other countries, prisons may 
thus contribute to the growing HIV-problem in Indonesia. Based on literature 
review and experience in one particular prison in Indonesia, this paper reviews 
the epidemiology of HIV in prisons, and the barriers, possible benefit as well as 
practical aspects of delivering effective HIV-prevention and care in prison. 
Epidemiology
In many countries, higher rates of HIV-infection are reported among prisoners 
compared to the general population.3 Injecting drug users (IDUs) are 
overrepresented in prisons and many of them are repeatedly incarcerated.3,4 
Sharing of contaminated injecting equipment possesses a high risk of transmission 
of HIV and outbreaks of HIV-infection in prisons have been documented from 
several countries.5,6 Apart from that, prison populations in general are dynamic 
with inmates going in and out the prisons all the time. The high proportion of 
IDUs and high turnover rate may contribute to the spread of blood borne viruses 
such as HIV among prisoners and to the general community.3  
Also in Indonesia, higher prevalence rates of HIV-infection have been reported 
from prisons. Official reports put the overall HIV-seroprevalence in prison at 15%, 
with rates up to 22% in Jakarta and 56% in Bali.3,7 A recent survey among more 
than 600 incoming inmates in Banceuy prison in Bandung, West Java, showed that 
7.2% were infected (Nelwan EJ, submitted for publication). The different rates that 
are reported from Indonesia may be due to selection bias, for instance differences 
in the proportion of IDUs that were included in serosurveys.
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Difficulties related to HIV-prevention and care in prison
Ideally, prison provides comprehensive programs for HIV that includes voluntary 
counseling and testing as well care and treatment for those that are infected. In addition, 
interventions for drug dependence and injecting drug use should be operational.8 
However, the implementation of such measures may be difficult for various reasons. 
First, prisons are no health institutions, and health programs in prison encounter many 
technical and budgetary constraints, such as a limited number of staff, the unavailability 
of laboratory testing or radiological examination, and inadequate supply of medication. 
Second, prison and prisoners face many health challenges besides HIV. Possibly 
due to the poor sanitation and overcrowding in prison, skin diseases like scabies, 
tuberculosis, and acute diarrhea are commonly found among inmates. Additional 
problems include management of co-morbid conditions, remoteness from HIV-
care sites, and organizational and budgetary constraints.
An additional problem which may further complicate HIV-prevention and –care in prison 
is the stigma that is surrounding HIV/AIDS among prison staff and prisoners. Being a 
very sensitive issue, HIV/AIDS programs and services must be responsive to the unique 
needs of vulnerable or minority populations within the prison.8 Knowledge, attitudes 
and beliefs among prison staff also needs to be considered since discrimination among 
that group may hamper adequate HIV-prevention efforts. Illustrative is a study that was 
carried out in an Indonesian prison and that showed that the attitude of prison staff 
towards inmates was strongly influenced by their knowledge of HIV/AIDS-transmission 
(Hinduan ZR, submitted for publication). Stigma also exists among prisoners themselves. 
HIV-seropositive inmates may be exposed to isolation due to fear of getting infected by 
sharing rooms, using the same food utensils or body contact. 
Finally, prison policy and specific technical issues in prison may hamper the 
implementation of programs focused on HIV-prevention and –care. For instance, 
prison authorities may be reluctant to introduce needle exchange because of 
security reasons. Condom distribution may suffer from fear among inmates to 
be identified as being sexually active with other (male) prisoners. In Indonesia, 
distribution of condoms, bleaching of needles and methadone were well accepted 
in some prisons such as in Kerobokan prison in Bali, but especially for needle-
exchange program, the actual implementation is still modest.9 
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Why is it important to provide HIV-prevention and -care in prison?
Despite the many problems facing HIV-prevention and -care in prisons, every 
effort should be made to provide services for prisoners, as a basic human right. 
Article 25 of the United Nations Universal Declaration of Human Rights states that 
everyone has the right to adequate health care.8 One should realize that prisoners 
that are facing a medical problem can only rely on the availability of health services 
inside prison, or referral by that same prison clinic to health institutes outside. 
Besides our moral obligation to provide HIV-prevention and -care for prisoners, 
there may also be a strategic reason to establish services in prison: effective HIV-
prevention in prison can make a substantial contribution to control of the HIV-
epidemic in the general community.  Imprisonment is a common and recurring 
event for IDUs in Indonesia. Inmates’ contact with the prison health care system 
provides an opportunity to offer HIV-screening to a population that is very difficult 
to reach otherwise.10
A final reason to provide HIV-prevention and -care in prison is its cost-
effectiveness.  The high prevalence of HIV-infection and over-representation of 
IDUs in prisons create unique opportunities for interventions which can be very 
delivered efficiently. Experience from Banceuy Prison, Bandung West Java show 
that targeted interventions can indeed to be used repeatedly and economically. 
Delivering HIV-services in prison - preconditions
From our experience, several issues should be considered when implementing 
HIV-prevention and -care in prison. The first and probably most important 
precondition is commitment from prison authorities, which is crucial and 
mandatory to implement and sustain any activity. Next, support from prison 
staff is crucial since these professionals will be in direct contact with the target 
population. All too often, HIV-prevention activities as well as HIV-counseling and 
testing are delivered in Indonesia by non-governmental organizations (NGO) 
or outside institutes without adequate involvement of prison staff. In these 
situations it may occur that advantages that are created by one party are undone 
by the other.
14
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The second precondition is a good collaboration with local health care providers. 
Prisons are not equipped to deliver specialized medical care and partnership 
with facilities for referral of patients and analysis of blood samples is needed to 
support the medical staff of the prison. These specialized facilities also need to 
be consulted after a diagnosis of HIV is made although most of case management 
can usually take place within the prison setting. In Bandung, a memorandum of 
understanding was made between by Hasan Sadikin Hospital and Banceuy prison 
in order to facilitate consultation of medical specialists inside prison and referral 
of patients or samples from prison to hospital. In collaboration with a primary 
health care center, diagnosis and treatment of tuberculosis was established (Table 
1).
Another issue to consider is the endorsement of HIV-services by the prison staff 
and prisoners. There is a hierarchic relationship between inmates and prison staff 
that access to interventions may therefore be limited by prison staff. An important 
motive for the prison staff may be (sometimes legitimate) concerns about their 
own health, in terms of transmission of HIV or other diseases. There is however 
generally a low level of knowledge on HIV and its transmission among Indonesian 
prison staff and improvement of knowledge is known to improve the tolerance of 
staff towards HIV-infected prisoners.  
The involvement of prisoners is equally important. Their help-seeking behavior 
and compliance with HIV-prevention and care depends on their trust. Experience 
in Banceuy prison has shown that inmates are willing to comply with services to 
improve their health. Not less than 94% of incoming inmates counseled for HIV, 
agreed to be tested (Table 2). Peer support proved instrumental for HIV-seropositive 
inmates to deal with psychological and practical issues related to testing, disclosure 
of HIV-status and starting antiretroviral treatment. In Banceuy prison, seventeen 
HIV-seropositive inmates voluntary meet on a weekly basis in a peer-group. 
Components of HIV-care in prison 
Prisoners do not directly benefit from anonymous serosurveys, and may lead to 
distrust and further stigmatization. Non-anonymous HIV-testing may be limited 
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because inmates may fear the negative consequences of having certain illness 
inside prison, or because confidentiality is not secured. Improvement of testing 
inside prisons may be achieved when general health care and voluntary counseling 
and testing (VCT) are integrated. In addition to that, offering VCT to all incoming 
inmates is a method to enable early diagnosis and timely treatment of HIV and 
may help to establish good relationships between prisoners and health care 
providers. Similarly, health services for resident inmates, for instance through 
outreach to prison blocks, will help to build trust and provide appropriate care. 
As mentioned above, confidentiality is a major concern for inmates who want to 
be tested or who were already found to be HIV-seropositive. Some issues should 
be carefully addressed such as the attitude of prison staff, appropriate facilities 
such as closed rooms for consultation, locked rooms for medical records and 
approach toward the medical history of inmates. 
So far, anti-retroviral treatment (ART) has been underprescribed in prisons. 
Although many barriers exist to treat all eligible HIV-infected prisoners, treatment 
reduces the costs associated with HIV-related complications and may encourage 
linkage to HIV-care in the community. One crucial issue in Indonesia is that 
prisons so far are not authorized to manage ART inside prison. Until now, all 
treatment is supplied from hospitals or other health institution outside prison, 
often via NGO’s. In the future it may be necessary to have the capacity to manage 
ART separately in prison clinics. Besides ART, care for those that are terminally ill 
should be improved, as well as possibilities for referral of patients to hospital or 
consultation of hospital specialists in prison. 
HIV-treatment in prison may actually be more effective than outside prison. In 
Banceuy prison in Bandung, so far 21 prisoners have been started on ART (Box 1). 
Prisoners receive their treatment daily under direct supervision, which allows for 
continuous monitoring and counseling. No single inmate has dropped out from 
treatment, and 16 from 17 patients (94%) examined had an undetectable plasma 
HIV-RNA after six months treatment. As a comparison, in hospital as much as 12% 
had dropped out from treatment after six months, and virological failure was 
detected in around 10% of patients.11 Possibly, good results can be achieved at a 
much lower costs in prison than outside, but so far this has not been examined. 
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Harm reduction measures for prisoners such as access to bleach, substitution 
therapy and sterile injection equipment have a positive impact for a population, 
particularly those vulnerable to HIV and HCV; states that fulfill these measures 
have implemented crucial public health policy. Ultimately, this approach benefits 
not only prisoners but also prison staff and the public, and does not entail 
lessening of the safety and security of prisons.12 Kerobokan prison in Bali has a 
successful story especially by implementing methadone substitution therapy to 
reduce HIV-infection.9
    
HIV-services in prison - issues to be resolved
Although HIV-prevention and -care can be implemented successfully in prison, many 
challenges are remaining. The most important issues which should be addressed 
are harm reduction, continuation of care for prisoners after release, and up-scaling 
and sustainability of HIV-prevention and care for all prisoners in Indonesia. 
Opioid substitution with methadone has been implemented successfully in many 
prison environments in the world.4 In Indonesia, Kerobokan Prison in Bali was the 
first prison to provide methadone which has enrolled 322 clients since August 
2005.13 Methadone has also been introduced in Banceuy Prison, Bandung, since 
August 2007. However, only nine inmates have been registered so far while some 
have also stopped while still in prison. Current policy in Banceuy prison does 
not allow other forms of harm reductions like provision of condoms and clean 
needles, or needle bleaching. The disparity between the apparent success of 
methadone in Bali and the low uptake and success in Bandung indicates that we 
need to understand more about addiction care for prisoners in Indonesia. 
The second issue which should be addressed is continuity of care after release from 
prison.14 HIV-prevention through harm reduction and HIV-treatment should be 
continued after inmates are released from prison. In practice, this may be difficult. 
Often, there is no established collaboration with health care providers outside prison, 
and logistic issues (costs, distance) may limit the accessibility of services.   
Establishing effective links between services in prison and in the community 
is essential. Such collaboration can improve the standards of care in prisons, 
support prison staff (including providing opportunities for training), ensure that 
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prison services reflect current national best practice, ensure the sustainability of 
prison programmes, and improve continuation of care after release from prison. 
The main problem that remains is budget. More cost-effective ways for providing 
general health care and early detection of HIV in prison should be identified. From 
these experiences, we recommend of the establishment of other referral prisons, 
to help ensure equal access to care for as many prisoners as possible. 
 
Conclusion
Prisons may fuel HIV transmission, but also may act as an appropriate place for HIV- 
prevention and -care, which may contribute significantly to control of HIV in general 
community, and which may be very cost-effective. Based on the experience in several 
prisons, a comprehensive and stepwise approach should be taken to establish HIV-care 
(Figure 1). Preconditions for HIV-services in prison include strengthened policy and 
commitment, collaboration with health facilities outside prison, and endorsement of 
services by prisoners and prison staff. Good general health care should be established 
first, as a starting point for widespread HIV-testing and treatment. Antiretroviral 
treatment can be delivered successfully, but continuation of care for prisoners after 
release is a matter of concern. Other issues which need further research or discussion 
are harm reduction strategies in prison, as well as up-scaling and sustainability of HIV-
prevention and care for all prisoners in Indonesia. 
The improvement in general health care, establishment of HIV-services and the 
serosurvey were financially supported by ‘IMPACT’ (Integrated Management of 
Prevention and Control and Treatment of HIV/AIDS), a 5-year program funded by 
the European Commission and CORDAID.
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Table 1. Banceuy Narcotic Prison – Implementation 
 
  2006                               MOU between Banceuy Prison and Hasan Sadikin Hospital
                                          Weekly consultation by hospital specialists
                                          Patients referral to Hasan Sadikin Hospital
  2007                               KAP study of prison staff related to stigma 
                                          Improved general health care
                                          Health screening for incoming inmates
                                          Blood sampling for HIV, HCV, HBV-serology, CD4
                                          Methadone Maintenance Treatment
  2008                               General health services linked with counselling and HIV testing
                                          Screening for tuberculosis
                                          Improve prison staff’s knowledge about HIV-AIDS
                                          HIV-care and treatment established, viral load 
                                          Peer support group HIV-positive prisoners
                                          Adherence and family counselling 
                                          Advocacy - World AIDS Day in prison
  2009                               Need assessment addiction care 
                                          Linking HIV-service inside prison with rehabilitation after release 
MOU, memorandum of understanding; KAP, knowledge, attitude and practice; 
HCV, hepatitis C virus; HBV, hepatitis B virus; CD4, CD4+ T-lymphocytes
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Table 2. Banceuy Narcotic Prison - Overview
   Capacity                                                      450 inmates
   Number of inmates                                  960; 48 new inmates/month
   Number of hospital beds                        15 beds
   Prison health staff*                                   4 GP, 2 dentists, 4 nurses, 3 support staff, 
                                                                                       1 psychology consultant, 1 laboratory technician
  History of injecting drug use                   17.3% of incoming inmates
  HIV-counseling and testing**                   818 inmates
  Major Health Problems***                        Upper respiratory tract infections (33.7%)
                                                                       Skin diseases (23.5%)
                                                                       Diarrhea (3.6%)
  HIV-positive#                                              63 inmates; 7.2% of incoming 539 inmates
  Anti-retroviral treatment#                       21 inmates 
  TB-treatment#                                            26 inmates 
  Methadone Maintenance Treatment#   9 inmates 
GP (general practitioner), * during study period additional of 2 GP, 3 nurse, 2 supporting staff, 
psychology and laboratory technician, ** since August 2007, *** diagnosis of 784 prisoners visiting 
the clinic, # until January 2009
22
Chapter 2
2
Figure 1. Preconditions and essential components of HIV-care in prison
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Summary
Objective 
To determine the prevalence and behavioural correlates of HIV, HBV and HCV 
infections among Indonesian prisoners and to examine the impact of voluntary 
counselling and testing for all incoming prisoners on access to antiretroviral 
treatment (ART).
Methods. 
In a non-anonymous survey in an Indonesian prison for drug-related offences, 
all incoming prisoners and symptomatic resident prisoners were counselled and 
offered testing for HIV, hepatitis B and C.
Results
Screening was performed in 679 incoming prisoners, of whom 639 (94.1%) agreed 
to be tested, revealing a seroprevalence of 7.2% (95% CI 5.2–9.2) for HIV, 5.8% 
(95% CI 3.9–7.6) for HBsAg and 18.6% (95% CI 15.5–21.6) for HCV. Of 57 resident 
prisoners tested, 29.8% were HIV-positive. HIV infection was strongly associated 
with injecting drug use (IDU; P < 0.001), but not with a history of unsafe sex. 
Screening of incoming prisoners was responsible for diagnosing and treating HIV 
in 73.0%, respectively, and 68.0% of HIV-positive individuals.
Conclusions
HIV and HCV are highly prevalent among incoming Indonesian prisoners and 
almost entirely explained by IDU. Our study is the first to show that voluntary HIV 
counselling and testing during the intake process in prison may greatly improve 
access to ART in a developing country.
Keywords: prisons, HIV infections, epidemiology, therapy, hepatitis, viral, human, 
substance abuse, intravenous, Indonesia
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Introduction 
The prevalence of HIV and other bloodborne infections is generally higher among 
prisoners than in the general community because of the over-representation of 
injecting drug users (IDUs) in prisons (Dolan et al. 2007). In high-income countries, 
prisons are therefore an important site to screen for HIV infection and initiate 
antiretroviral treatment (ART), as a way to increase access to HIV care (Springer 
et al. 2007; Zaller et al. 2007). Data regarding HIV and IDU from low-income and 
medium-income countries are less clear. For instance, studies on HIV prevalence 
rates among IDU prisoners are scarce and usually anonymous (Dolan et al. 2007), 
while reports of HIV ⁄ AIDS treatment programmes in prisons are limited to the 
outcomes of pilot projects (Spaulding et al. 2002; Springer et al. 2007) or include 
only patients with symptoms (Wilson et al. 2007). 
This study was carried out in Indonesia, which has one of the fastest growing 
HIV epidemics in Asia (Pisani et al. 2003; AIDS Alert 2005). IDU is the main factor 
driving the epidemic in Indonesia, and patients are generally diagnosed at a very 
late stage of disease (Celentano et al. 2001; Pisani et al. 2003; Solomon et al. 
2009). Prevalence rates above 50% have been reported among IDUs, while the 
HIV prevalence in the general population is fortunately still low (0.2%) (Mathers 
et al. 2008; Ministry of Health of Indonesia 2008). Other bloodborne infections 
such as hepatitis B and C (HCV) are also more common among IDUs compared to 
the general population (Allwright et al. 2000; Weinbaum et al. 2005; Butler et al. 
2007). In 2006, more than 110 000 people were imprisoned in Indonesia, with 
around 30 000 convicted for drug-related offences, of whom 30–50% were IDUs 
(Directorate General of Correction 2007). Sentinel surveys have reported HIV 
prevalence rates up to 50% in Indonesian prisons (Ministry of Health of Indonesia 
2007). However, these surveys were small and may have suffered from selection 
bias. HBV and HCV were not included in these surveys, no behavioural correlates 
were measured, and the implications of testing were not examined.
The aim of this study was therefore to determine the prevalence and behavioural 
correlates of HIV, HBV and HCV infections among Indonesian prisoners and to 
examine the impact of voluntary counselling and testing for all incoming prisoners 
on access to ART.
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Materials and Methods
Setting. 
The study was conducted in Banceuy prison, Bandung, one of the two prisons 
appointed for drug-related offences such as selling or dealing drug or drug use 
in West Java (40 million inhabitants), Indonesia. This prison has a maximum 
capacity for 450 prisoners, but at any point in time there are about 900 – 1000 
prisoners and every month 30–50 new prisoners come in. Health care is provided 
in an outpatient clinic and in a small inpatient clinic by one general practitioner, 
two dentists and three nurses. Within 1 day after arrival, prisoners are medically 
examined and prisoners who are ill are admitted directly in the prison clinic. For 
HIV counselling and testing, the prison has collaborated with psychologists from 
Padjajaran University, Bandung, since 2004. Since 2006, Hasan Sadikin hospital 
in Bandung, the referral hospital for West Java, assists in the provision of health 
care by means of weekly consultation in prison by internists and other medical 
specialists, referral of patients to the hospital and training of nurses and a 
laboratory technician. Three additional physicians trained to provide counselling 
assisted during the conduction of the research in the clinic.
Cross–sectional survey. 
Between August 2007 and January 2009, a cross–sectional study was performed, 
with approval of the ethical committee of Padjajaran University, Bandung. 
All incoming prisoners were referred to the prison clinic, those who were 
symptomatic immediately and those who were asymptomatic within 3 months. 
In the clinic, prisoners were informed about the study and counselled about 
HIV. Written informed consent was asked for collecting medical and behavioural 
information and testing for HIV, HBV and HCV. If consent was given, information 
about sociodemographic data, medical history, physical status and risk behaviour 
related to HIV infection was recorded using a structured questionnaire. A physical 
examination was carried out, and blood was collected for serological testing. 
All testing was voluntary, free of charge and confidential, and counselling was 
performed before and after HIV testing. 
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Apart from the incoming prisoners, ‘resident’ prisoners (who had been in prison 
for at least 3 months in August 2007) were included if they presented at the 
prison clinic during the study period with symptoms or signs or self–reported risk 
behaviour related to HIV infection. These resident prisoners underwent the same 
procedure as the incoming prisoners. When the study was initiated in August 
2007, there were 886 resident prisoners in Banceuy prison.
All HIV–positive subjects received further laboratory testing including the 
measurement of CD4 T–cell count. ART was started following national and WHO 
guidelines, under guidance from specialists at the Hasan Sadikin hospital. 
Laboratory testing. 
HIV antibodies were measured using commercially available rapid tests 
(Determine HIV–1/2, Abbott laboratories, Tokyo, Japan; SD HIV–1/2 3.0, Standard 
Diagnostic, Inc, Kyonggi–do, Korea); enzyme immunoassay (EIA; Virolisa, Index 
Union Diagnostic, Korea); and electrochemiluminescence immunoassay (ECLIA; 
HIV combi, Roche, Mannheim, Germany) in accordance with national guidelines. 
HBsAg, anti–HBs, anti–HBc and anti–HCV were measured by ECLIA (Roche 
diagnostic, Mannheim, Germany). External quality control of HIV, HBV and HCV 
serology (National Serology Reference Laboratory, Australia) showed 100% 
accuracy. CD4 cell measurements were taken using Facscount flow cytometry 
technology (BD Biosciences, Jakarta, Indonesia).
Data analysis. 
The prevalence of infection with HIV, HBV and HCV was measured in the two 
groups of prisoners, the unselected group of incoming prisoners and the selected 
group of resident prisoners presenting to the clinic. Risk factors and symptoms 
were compared for seropositive and seronegative prisoners, using chi-squared 
test for nominal and ordinal variables, t–test for normally distributed and non-
parametric Mann–Whitney U-test for non–normally distributed continuous 
variables. Multivariate logistic regression was used to calculate odds ratios (OR) 
and 95% confidence intervals (CI) for risk factors associated with infection. Data 
were analyzed using SPSS, version 13.0 (SPSS) for windows.
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Results 
During an 18-months period, a total of 737 prisoners gave written informed consent 
to participate in the study, consisting of 679 incoming prisoners and 58 resident 
prisoners (Figure 1). After informed consent, 40 (5.9%) of the incoming prisoners 
refused a HIV test. Compared to those who agreed to be tested, fewer indicated a 
history of IDU (0% vs. 19.3%), fewer had been in prison before (15.8% vs. 20.2%), and 
fewer had physical symptoms suggesting possible HIV infection (data not shown). 
Among the 58 resident prisoners included, only one refused a HIV test.
The average age of the study population was 31.3 (range 17–63) years and 
96.5% were men. Ten percent had no formal education, 20% had graduated from 
elementary school, 30% had graduated from junior school, 35% were from high 
school, and 5% had been to university. More than half (51.4%) were married, 
and 9.7% were divorced or widowed. A history of IDU was reported by 19.3% 
of incoming prisoners. Twenty percent of incoming prisoners had been in prison 
before, for a cumulative average of 8.3 (range 0.3–37.6) months. Twenty–two 
percent of resident prisoners had been imprisoned before, and their cumulative 
average time spent in prison was 18.4 (7.0–32.0) months.
Seroprevalence of HIV, HBV and HCV infections. 
In Table 1, the seroprevalence of HIV, HBV and HCV is presented for incoming 
and resident prisoners. The seroprevalence rate for the incoming prisoners was 
7.2% (95% CI 5.2–9.2) for HIV, 5.8% (95% CI 3.9–7.6) for HBV (HBsAg–positive) 
and 18.6% (95% CI 15.5–21.6) for HCV. HCV co-infection was strongly associated 
with HIV infection (P<0.001). Regarding HBV infection, almost half of all incoming 
prisoners were positive for anti–HBs, anti–HBc or both. HBsAg–positive was not 
associated with HIV infection, but isolated anti–HBc antibody (anti–HBc alone) 
was more common in HIV–positive than in HIV–negative incoming prisoners (19.6 
vs. 5.1%, P<0.001). HBV–HCV coinfections were rare, both among HIV–positive and 
HIV–negative incoming prisoners (Table 1). Anti–HBc alone was more common in 
HCV–infected prisoners (14.3 vs. 5.0%; P<0.001). Among the selected group of 
resident prisoners, the HIV prevalence was higher than among incoming prisoners, 
while infection with HBV and HCV appeared not much different (Table 1). 
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Signs, symptoms and risk behaviour according to serostatus. 
HIV–positive prisoners reported more symptoms associated with HIV (Table 2). 
A limited number of prisoners were examined for dermatological complaints; 
scabies was less and seborrhoic dermatitis was more common among HIV–
positive prisoners. 
General characteristics and risk behaviour according to HIV status are shown in 
Table 3. A history of IDU was strongly associated with HIV infection; 37.6% of 
incoming prisoners who reported a history of IDU were HIV–infected, compared 
to 0.4% of those who denied IDU (P<0.001). Information on frequency of needle 
sharing was collected but no association with HIV serostatus was found (data 
not shown). Among prisoners with a history of IDU, injecting in prison was 
more common in HIV–positive than in HIV–negative individuals (70.6 vs. 29.4%, 
P<0.001). In univariate analysis, HIV–positive prisoners also more often had a 
history of previous imprisonment than HIV–negative prisoners (38.6 vs. 18.5%, 
P<0.001) although the cumulative time spent in prison was similar in both groups. 
Unprotected sex with sex workers or casual partners was reported by more than 
95% of prisoners in both groups. 
Multivariate analysis for factors associated with HIV infection is shown in Table 4. After 
adjustment for confounding IDU, other factors (previous imprisonment and tattoos) 
were no longer associated with HIV infection. Unprotected sex with sex workers was 
not significantly associated with HIV infection in univariate nor multivariate analysis. 
HBV–infection (detectable HBsAg) was not associated with IDU but was significantly 
more common among those with a tattoo (78.9 vs. 56.1%, p=0.006), also after 
adjustment for IDU (adjusted OR 3.40 95% CI: 1.5–7.6, p=0.03). Other risk factors 
such as previous imprisonment and unprotected sex with sex workers showed no 
significant association with HBV infection (data not shown). The same was true 
when prisoners who were positive or negative for any HBV marker were compared 
(data not shown). Similar to HIV, infection with HCV was more common among 
those with history of IDU (77.3 vs. 6.6%, p<0.001), having a tattoo (81.4 vs. 51.7%; 
p<0.001) or previous imprisonment (31.8 vs. 17.2%, p<0.001). After adjustment 
for a history of IDU, having a tattoo remained significantly associated with HCV 
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infection (adjusted OR 2.27, 95% CI 1.22–4.22), while previous imprisonment was 
no longer associated (adjusted OR 1.44, 95% CI 0.77–2.69). Among prisoners with 
a history of IDU, injecting in prison was more common in HCV–positive than in 
HCV–negative individuals (82.4 vs. 17.6%; P<0.197). Unprotected sex with sex 
workers was associated with HCV infection in univariate analysis, but not after 
adjustment for confounding by IDU (adjusted OR 1.81, 95% CI 0.56–5.88). 
Clinical implication of HIV testing. 
The median CD4 cell counts in the 63 HIV–positive prisoners were 246 cell/
mm3 (range 5–726). Seventeen incoming (37.0%) and eight HIV–infected 
resident prisoners (47.0%) had a CD4 cell count <200/mm3, an indication to 
start antiretroviral therapy according to the Indonesian guidelines (Figure 1). 
Treatment was started in all prisoners with CD4 cells <200/mm3. Screening of 
incoming prisoners initiated diagnosing and treating HIV in 73.0%, respectively, 
and 68.0% of HIV–positive prisoners (Figure 1). Of 25 patients who started ARV 
in prison, no one stopped treatment (median follow–up 6.0 months, range 0–10), 
and all but one had an undetectable plasma HIV RNA after 6 months of treatment. 
Discussion 
High prevalence rates of HIV, HBV and HCV were found in an Indonesian prison. 
IDU was a very strong risk factor for HIV and HCV, but not HBV, while tattooing 
was independently associated with HBV and HCV infection. Unprotected sex with 
sex workers and others, although very commonly reported, was not a risk factor 
for HIV infection. Finally, HIV counselling and testing in prison revealed 73.0% of 
HIV diagnoses and started 68.0% of HIV treatment. 
The willingness of prisoners to be tested was very high compared to studies 
performed elsewhere (Behrendt et al. 1994; Altice et al. 2005).  This may be 
attributed to a comprehensive and stepwise approach in establishing HIV care. 
Before the study was started, prison policy and commitment were strengthened, 
good collaboration with health facilities outside prison was established, and 
general health care and counselling inside prison were improved (Nelwan et 
al. 2009). Both prison staff and prisoners were involved in the introduction of 
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HIV testing and treatment. Testing can have a direct benefit for prisoners, but 
it also carries the risk of stigmatization (Morrison & Gilchrist 2001; Derlega et 
al. 2008). Unlike previous anonymous surveys (Behrendt et al. 1994), prisoners 
were informed about the results, and all those who were positive were tested for 
CD4 cell counts and offered treatment if indicated. As such, we demonstrate that 
also in low–income countries, prisons may offer a unique environment to improve 
access to care for IDU, thereby helping to bridge HIV prevention and control to the 
general community (Freudenberg 2001). 
A high prevalence of HIV was found among unselected prisoners, much higher than 
among the general population in Indonesia (0.2%) (Ministry of Health of Indonesia 
2008). Previous surveys of HIV prevalence in Indonesian prisons, including the 
prison where this study was conducted, showed higher figures (Direktorat Jendral 
Pemasyarakatan 2007; Dolan et al. 2007). However, these studies were much 
smaller and may have suffered from selection bias, with an over–representation 
of prisoners with physical symptoms or HIV–associated risk behaviour, like in the 
group of resident prisoners tested in this study (HIV prevalence 29.8%). The current 
figure of 7.2%, based on examination of 94.1% of incoming prisoners, is therefore 
more accurate to estimate the HIV prevalence among incoming prisoners. In most 
countries, HIV prevalence rates are higher in prison than in the general community 
(Dolan et al. 2007). However, the difference as found in this study is higher than in 
many other settings. For instance, in an anonymous recent survey in Thailand, 6.0% 
were found positive, compared to 1.5% among the general community in Thailand 
(Wilson et al. 2007). This is most likely due to the high percentage of IDUs in this 
prison and the strong association of HIV with IDU in Indonesia. In parallel, the 
higher prevalence of HIV among resident prisoners when compared to incoming 
prisoners in our study is maybe because of selection bias; alternatively, it may 
reflect ongoing HIV transmission in prison.
Similar to HIV, a much higher prevalence of HCV infection (18.6%) was found 
among incoming prisoners compared to the general population in Indonesia (2.1–
3.9%) (Sulaiman et al. 1995; Akbar et al. 1997). HCV infection was predominantly 
found among IDUs, which made up 19.2% of prisoners. We also found that most 
HIV–positive incoming prisoners (89.1%) were HCV co-infected, in line with other 
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reports on bloodborne infections in IDU (Thaisri et al. 2003). HCV was more 
common than HIV, which can be explained by the easier transmission of HCV 
through needle sharing among IDUs (Stark et al. 1996). 
Almost 6% of prisoners were positive for HBsAg and around 50.0% for any marker 
of HBV infection. HBV was not associated with IDU, suggesting that HBV infection 
is not so much concentrated among IDUs but rather a more generalized problem 
maintained by sexual or vertical transmission. In addition to this, tattooing is 
common in prison populations and as reported elsewhere seems to be associated 
with HBV and HCV infections (Samuel et al. 2001; Wilson et al. 2007). This is an 
important finding because the general awareness of the risk of tattooing is very 
low in Indonesia. Also in line with previous studies, anti–HBc alone was associated 
with HIV and HCV infections, possibly due to a deficient immune response in these 
conditions (Ferreira et al. 2009; French et al. 2009). 
Injecting drug use was found to be the single strongest risk factor for HIV, typically 
reflecting the epidemic in Indonesia and the over–representation of IDUs in this 
prison. Almost 37.6% of IDUs entering this prison were already HIV–infected. 
Many reported previous imprisonment, often in other prisons. In addition, 
many prisoners reported ever having injected inside a prison, and this was 
independently associated with HIV infection, similar to studies in other settings 
(Thaisri et al. 2003). Clean needles are scarce in prison, as needle and syringe 
exchange programmes are not operational in most prisons, in Indonesia and 
abroad (Mesquita et al. 2007). 
No other risk factors were associated with HIV infection. Previous imprisonment 
and tattoos were more common among HIV–positive prisoners but this was 
because of confounding by IDU. Unprotected sex with sex workers or casual 
partner was common, but showed no association with HIV infection. However, 
many HIV-infected prisoners are married or have stable partners, and it is this 
category of ‘low-risk females’ which seem to have a substantial risk of becoming 
HIV-infected. This finding underlines the importance to focus HIV prevention in 
Indonesia on IDUs, through needle exchange, opioid substitution and condoms to 
protect their female partners. 
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This is one of the largest studies on bloodborne viruses in prison from a developing 
country. As only a single prison was included, the data are not representative 
of the whole of Indonesia and being cross–sectional, transmission inside prison 
could not be established with certainty. Also, the IDU status was determined 
by self–report and prisoners may be reluctant to admit a history of IDU, fearing 
possible consequences such as additional punishment. Despite these limitations, 
it can still be concluded that bloodborne viruses are common among Indonesian 
prisoners and that HIV prevention should primarily target IDUs. The data also 
confirm the need for HIV care (both testing and treatment) in prison, which is the 
exception rather than the rule in prisons in developing countries. Of note, also in 
western countries, the opportunity for timely diagnosis of HIV though screening 
in prison is often missed. For instance, screening is mandatory in prisons in South 
Carolina, USA, but almost 50% of 4000 subjects with a criminal record who were 
diagnosed with HIV infection in this state had not been screened during recent 
imprisonment. Feasibility and cost–effectiveness of more widespread screening 
for HIV in prisons should be evaluated, either for all prisoners or only for those 
with a history of IDU or symptoms suggesting HIV infection. HIV care should 
be combined with harm reduction programs in prison, and more research is 
needed to identify the most effective strategies of harm reduction inside prisons. 
Continuation of ART after release from prison is another pressing issue also in 
western countries; a recent study showed that not more than 30% of Texas prison 
inmates receiving ART while incarcerated filled an initial ART prescription within 2 
months of their release (Baillargeon et al. 2009). 
In summary, HIV and HCV are highly prevalent in Indonesian prisoners and 
can almost entirely be explained by IDU. Tattoo was a risk factor for HBV and 
HCV infection. Unprotected sex, although almost universally reported, was not 
associated with HIV infection but may contribute to spread of HIV from IDUs or 
increased risk of IDUs’ sexual partners in the general community. Finally, voluntary 
counselling and testing of incoming IDU prisoners seem a feasible and effective 
way to increase the detection and treatment of HIV among prisoners.
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Figure 1. Flow of incoming and resident prisoners. *Prisoners presenting at prison clinic 
with signs, symptoms and or risk behavior of HIV infection. ART, antiretroviral treatment. 
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Table 1. Seroprevalence of HIV, HBV, and HCV 
Incoming prisoners
(n=639)
Resident prisoners
(n=57)
HIV –positive 46/639 (7.2) 17/57 (29.8)
       Anti–HCV–positive 41/46 (89.1) 11/17 (64.7)
       HbsAg–positive 2/41 (4.9) 0
HIV–negative 593/639 (92.8) 40/57 (70.2)
       anti–HCV–positive 77/593 (12.9) 4/40 (10.0)
       HbsAg–positive 30/565 (5.3) 1/37 (2.7)
HBsAg–positive 37/635 (5.8) 1/57 (1.8)
Anti–HBs and anti-HBc–positive 222/635 (35.0) 18/53 (34.0)
Isolated anti–HBc antibody 39/610 (6.3) 8/49 (16.3)
Anti–HBs alone 47/632 (7.4) 8/52 (15.4)
Any HBV marker–positive 251/631 (39.8) 20/53 (37.7)
Anti–HCV–positive 118/635 (18.6) 15/57 (26.3)
HBsAg and anti–HCV–positive 5/606 (0.8) 0
HIV, anti–HCV and HbsAg–positive 4/606 (0.7) 0
Data are shown as n/N (%). 
Table 2. Signs and symptoms of prisoners according to HIV serostatus
 HIV–positive, 
(n=63)
HIV–negative, 
(n=633) P
Weight loss 15/63 (25.9) 56/626 (8.9) < 0.001
Diarrhea (> 3 weeks) 5/59 (8.5) 5/628 (0.8) < 0.001
Fever (> 1 month) 13/59 (22.0) 9/628 (1.4) < 0.001
Chronic cough (> 3 weeks) 10/59 (16.9) 28/628 (4.5) < 0.001
Oral thrush 7/59 (11.9) 6/627 (1.0) < 0.001
Scabies 4/22 (18.2) 67/179 (37.4) 0.80
Seborrhoic dermatitis 4/22 (18.2) 9/176 (5.1) 0.02
Data are shown as n/N (%).
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Table 3. Characteristics of prisoners according to HIV serostatus
  HIV–positive, 
(n=63)
HIV–negative, 
(n=633)
P
Age (range, years) 28.0 (23–54) 29.0 (17–63) 0.33
Male 60/63 (95.2) 612/633 (96.7) 0.55
Previous imprisonment 22/57 (38.6) 114/618 (18.5)  < 0.001
Cumulative time in prison (range, months) 8.5 (0.3–37.6) 8.9 (0.4–65.7) 0.94
History of injecting drug use 58/61(95.1) 82/625 (13.1) < 0.001
          Injecting in prison 24/61 (39.3) 10/625 (1.6)  < 0.001
Unprotected sex with sex worker 60/63 (95.2) 607/633 (95.9) 0.80
Unprotected sex with casual partner 55/63 (87.3) 607/632 (96.0) 0.002
Tattoo 48/56 (85.7) 341/621 (54.9) < 0.001
Piercing 6/63 (9.5) 87/633 (13.7) 0.35
Data are presented as n/N (%) unless stated otherwise.
Table 4. Factors associated with HIV infection
Crude OR 95% CI Adjusted OR 95% CI
IDU 128.0 39.2–418.1 104.8 30.9–355.3
Previous imprisonment 2.77 1.57–4.92 1.33 0.63–2.78
Tattoo 4.91 2.28–10.55 1.74 0.71–4.23
Age 1.02 0.98–1.05 0.98 0.93–1.04
Unprotected sex with sex worker 0.28 0.12–0.71 1.87 0.48–7.4
IDU, injecting drung use.
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ABSTRACT
Background: Risky behavior, particularly among specific target populations, is the 
main contributor to the worldwide, ongoing HIV epidemic. Prisoners are such a 
target population.  Different aspects of impulsivity can be linked to a wide range of 
their risky behaviors, including alcohol/substance abuse and sexual risk behavior. 
Both are linked to the transmission of HIV, as well as hepatitis B and C and syphilis. 
Studies delineating different aspects of impulsivity in relation to risky behavior 
are scarce, particularly among females and Asian populations. Objective: To 
explore the relationship between different aspects of impulsivity, risky behavior 
and infectious diseases among female prisoners in Indonesia. Methods: A cross-
sectional, bio-behavioral study was conducted among female inmates (N = 214) at 
the Pondok Bambu Prison, Jakarta. Impulsivity and risky behaviors were assessed 
using self-report questionnaires. Serological tests were used to detect infectious 
diseases (HIV, hepatitis B/C and syphilis). The relationships between different 
aspects of impulsivity, risky behavior and related infections were tested. Results: 
Motor and reward-related impulsivity are predictive for problematic alcohol 
use, reward sensitivity is furthermore predictive for problematic drug use and 
cognitive and lifestyle impulsivity for sexual-related risk behavior. Eventually, 
this motor, reward and lifestyle impulsivity also seem to predict the presence of 
infectious diseases. Conclusions: Different aspects of impulsivity are relevant for 
different types of risky behaviors and associated infectious diseases in Indonesian 
female prisoners. Future prevention strategies need to target specific aspects of 
impulsivity in specific target populations.
Keywords: HIV, hepatitis, impulsivity, risk behavior, substance use, syphilis 
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INTRODUCTION
In some countries, the numbers of new human immunodeficiency virus (HIV) 
infections are declining over the last years (UNAIDS, 2016). However, in others it 
remains static and some countries even experienced increases in new HIV infections. 
This is presumably caused by the different risk populations living in these countries, 
sometimes not experiencing the right prevention services (UNAIDS, 2016). 
Risky behaviors such as sharing needles to inject drugs and having unprotected 
sexual contact, contribute to the ongoing spread of HIV and other sexual 
transmitted diseases (STIs) such as Hepatitis B/C (HBV/HCV) and syphilis. These 
risk behaviors are especially overrepresented in prison (UNAIDS, 2016), a place 
where people have less access to harm reduction measures: often there are 
no condoms or clean needles available, sometimes HIV treatment stops and 
e.g. rape is common (UNAIDS, 2014). It is not surprising that the prevalence of 
HIV is 5 times higher in prison populations compared to the general population 
(UNAIDS, 2016). Furthermore, risk behavior studies among prisoners have most 
frequently included males, because they represent the vast majority of detainees 
(Walmsley, 2006). However, in recent years female prisoners have contributed as 
much as males to the transmission of HIV and co-infections (Carvell & Hart, 1990; 
Gyarmathy, Neaigus, & Szamado, 2003; Hammett, 2006). Recently, injecting drug 
use (Greenfield, Back, Lawson, & Brady, 2010) and unsafe sexual practices (Pruss-
Ustun et al., 2013) becomes more frequently found among women than before. 
Impulsivity seems to be a route to risky decision-making and subsequently to risky 
behavior (Nunes, Andrade, Galvão-Castro, Bastos, & Reingold, 2007; Pedrana, 
Aitken, Higgs, & Hellard, 2008). In general, people scoring high on impulsivity 
show more negative life outcomes such as substance use, criminal activities, 
and certain infectious diseases (Giotakos et al., 2003). Impulsivity is broad 
construct that involves a tendency to act without deliberate thinking, reflection, 
or consideration of the consequences (Sanbonmatsu, Strayer, Medeiros-Ward, 
& Watson, 2013). It also includes a number of independent components such 
as impaired inhibitory motor control, cognitive dyscontrol, short time reward 
sensitivity, and sensation seeking behavior, leading to an impulsive life style (Dick 
et al., 2010; Hamilton, Sinha, & Potenza, 2012). Previous research shows that 
different aspects of impulsivity may be relevant to different types of risky behavior 
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(Krishnan-Sarin et al., 2007). For example, sensation seeking or an impulsive 
lifestyle is associated with sexual risk behavior (Shirley J Semple, Jim Zians, Igor 
Grant, & Thomas L Patterson, 2006), while reward sensitivity is more likely to be 
associated with drug use (Margolin et al., 2007). Impulsivity is reported to be 
higher among people when they use substances like alcohol or drugs, which in 
turn can lead to e.g. unprotected sexual contact (Charnigo et al., 2013; Robbins 
& Bryan, 2004; S. J. Semple, J. Zians, I. Grant, & T. L. Patterson, 2006). Because 
impulsivity is associated with risk-taking behaviors (Black, Serowik, & Rosen, 
2009) and increased probabilities of contracting HIV and STIs like Hepatitis B and 
C (Bornovalova, Gwadz, Kahler, Aklin, & Lejuez, 2008), impulsivity represents an 
important construct contributing to public health concerns. 
Information on the role of impulsivity in risky behavior is mostly derived from 
studies conducted among Western male populations (Pedersen, Molina, 
Belendiuk, & Donovan, 2012). It is however clear, that the construct of impulsivity 
may have different presentations in different cultures (Kong et al., 2013) and 
different genders (Stoltenberg, Batien, & Birgenheir, 2008). Even as the variability 
in common risk behavior across different countries and populations, e.g. sexual 
risk behavior among men who have sex with men (MSM) in America and young 
women in sub-Saharan Africa, or drug use in Eastern Europe and Asia (Beyrer 
& Karim, 2013; Catania et al., 1991; Gorbach, Murphy, Weiss, Hucks-Ortiz, & 
Shoptaw, 2009; Knight et al., 2007). Research into the details of this subject across 
Asian populations is lacking. In Indonesia, with one of the fastest growing HIV-
epidemics in Southeast Asia, females are increasingly becoming infected (Ministry 
of Health of Indonesia, 2014; UNAIDS, 2015). Especially women who inject drugs 
and/or live in prison are at greater risk (Larney, Mathers, Poteat, Kamarulzaman, & 
Degenhardt, 2015). Based on previous literature, it is presumably that impulsivity 
plays a role in the understanding of risk behavior among this population. 
This study is performed to get a better view of risk behaviors and the possible 
role of impulsivity to trigger it, among female inmates in an increasing HIV-
epidemic country like Indonesia. In this study, we set out to evaluate different 
aspects of impulsivity (motor impulsivity, cognitive impulsivity, reward sensitivity 
and impulsive life style) in relation to substance use and sexual related risk 
behavior, and the prevalence of risk behavior related infections (HIV, HBV, HCV 
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and syphilis) among an at-risk target-population for these kind of infections. We 
investigated the following hypotheses, if among these female prisoners: a) there 
is an association between different aspects of impulsivity and risky behaviors; b) 
there is an association between these aspects of impulsivity and the prevalence of 
infectious diseases (HIV, HBV, HCV and syphilis) and, c) the relationship between 
impulsivity and the prevalence of infectious diseases is mediated by risk behavior.
METHODS
Study design and subjects
This study was a cross-sectional bio-behavioral study, combining behavioral data with 
a serosurvey on the presence of infectious diseases among female prisoners in Pondok 
Bambu Prison, Jakarta. All new incoming prisoners (N = 300) were offered serological 
testing for HIV, HBV, HCV and syphilis. In addition, those prisoners participating in the 
serosurvey were asked to participate in the behavioral study part. Six inmates refused 
the serosurvey. Of the 294 participating in the serosurvey, 44 women could not be 
traced for the behavioral assessment, 6 women refused to participate in this part of 
the study, and 30 were excluded due to illiteracy or a lack of comprehension of the 
assignments. This resulted in a final number of 214 participants.
Behavioral assessments
Process of translation and adaptation
All measurements were self-report questionnaires, concerning the past and mostly 
present occurrence of risk behavior and impulsivity traits. Three questionnaires 
concerning risky behavior were accessible in Indonesian. Although reliability data 
of these translated versions were not available yet, we used these measurements 
based on previous research experience with the questionnaires and good 
psychometric characteristics of the English versions. The three questionnaires 
concerning impulsivity were not available in Indonesian. These were first 
translated from the original English versions by two native Indonesian speakers, 
with a fluent English language level. This was followed by a translation back into 
English by one native English speaker, also disposed with Indonesian language 
abilities. Any discrepancies were discussed and solved in a consensus meeting 
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with all translators and the executive researchers, in line with the WHO guidelines 
(World Health Organization, 2015).
Demographics
Demographic variables as age, education, marital status and occupation were 
assessed using a self-report questionnaire. 
Assessment of impulsivity 
The Barratt Impulsiveness Scale (BIS-11) was used to assess cognitive and motor 
impulsivity (Patton, Stanford, & Barratt, 1995). It consists of 30 items, scoring on a 
four-point Likert scale and covering 3 domains of impulsivity: BIS-Attention (quick 
decision-making, 8 items), BIS-Motor (acting without thinking, 11 items) and BIS-
Non-planning (lack of forethought, 11 items). The BIS-11 has excellent internal 
consistency and retest reliability (Patton, Stanford, & Barratt, 1995).
The Behavioral Inhibition System and Behavioral Activation System (BIS/BAS) was in 
general used to assess impulsive lifestyle (Carver & White, 1994). It consists of 20 items, 
scored on a four-point Likert scale. The BIS scale measures neuroticism and negative 
effect (avoidance tendencies), consisting of 7 items about regulating aversive motives. 
The BAS scale measures extraversion and positive effect (approach tendencies) and 
consists of 3 subscales: BAS-Drive (pursuing desired goals, 4 items), BAS-Fun-seeking 
(desire for new rewards, 4 items) and BAS-Reward (reward responsiveness, 5 items). 
The BIS/BAS has good psychometric properties (Carver & White, 1994). 
The Sensitivity to Punishment & Sensitivity to Reward Questionnaire (SPSRQ) 
was used to assess reward-related impulsivity (Torrubia, Ávila, Moltó, & Caseras, 
2001). It contains 48 items (yes/no) and measures punishment and reward 
responsiveness/impulsiveness. Half of the items are summed in an index of 
‘sensitivity to punishment’ and half as an index of ‘sensitivity to reward’. The SPSRQ 
is a reliable measure of punishment- and reward-related sensitivity, independent 
of personality factors (Torrubia, Ávila, Moltó, & Caseras, 2001).
Assessment of risky behaviors 
The Alcohol Use Disorders Identification Test (AUDIT) is a simple method developed by 
the World Health Organization (WHO) to screen for excessive drinking patterns, which 
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can be predictive for subsequent transmission risk behavior (Bohn, Babor, & Kranzler, 
1995). It consists of 10 items with a five-point Likert scale. The first 3 items cover the 
consumption pattern, the other 7 assess alcohol dependence and the consequences of 
alcohol use (Skinner, 1982). For women, a total score of 8 or higher indicates harmful 
alcohol use (Maisto, Conigliaro, McNeil, Kraemer, & Kelley, 2000; Saunders, Aasland, 
Amundsen, & Grant, 1993). The AUDIT has excellent psychometric properties and has 
been used in different populations worldwide; it is therefore commonly applied in 
clinical practice (Meneses-Gaya, Zuardi, Loureiro, & Crippa, 2009). 
The Drug Abuse Screening Test (DAST) is a self-report questionnaire, including 
10 dichotomous items (yes/no), used to screen for problematic drug use (Yudko, 
Lozhkina, & Fouts, 2007). A DAST total score of 3 or higher indicates that a person 
is likely to have drug use problems. The reliability of this instrument to identify 
drug use problems is shown in various populations (Yudko, Lozhkina, & Fouts, 
2007) and at this moment it is commonly used to screen for drug use problems in 
clinical practice (Nydegger, Ames, Stacy, & Grenard, 2014).
The Sexual Risk Behavior (SRB) questionnaire was used to assess sexual risk behavior 
(Boekeloo et al., 1994). It entails 20 items regarding risky sexual behavior e.g. condom 
use, amount of sexual partners etc. (Boekeloo et al., 1994). Questions applying only to 
male respondents (e.g. insertive anal sex) were excluded, leaving 16 questions. Three 
items have a four-point scale, 5 items have a six-point scale, and 8 items have binary 
outcomes (yes/no).
Detection of risk behavior related infections
Screening for HIV, HBV, HCV and syphilis was done by serology testing. Screening 
for HIV was done by chemiluminescent microparticle immunoassay (CMIA), a rapid 
diagnostic HIV-1/2 test (PT Oncoprobe Utama), and confirmed by enzyme-linked 
fluorescence assay (ELFA, VIDAS® HIV DUO ULTRA). HBV serology was performed 
by using CMIA method (ARCHITECT HBsAg qualitative assay and ARCHITECT HBsAg 
Qualitative Confirmatory Assay by ABBOTT Diagnostics®) for HBsAg and Anti-HBc 
tested using CMIA method (using ARCHITECT Anti-HBc IgM assay and ARCHITECT 
Anti-HBc II assay by ABBOTT Diagnostics®). Active HBV infection was diagnosed if 
hepatitis B surface antigen (HBsAg) and anti-hepatitis B core antigen (anti-HBc) 
were positive. HCV was determined by using in vitro diagnostic immunoassay for 
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the detection of immunoglobulin G (IgG) antibodies to Hepatitis C Virus (using 
ADVIA Centaur HCV assay), syphilis was tested with Rapid Plasma Reagin (RPR) test 
(using IMMUTREP RPR by Omega Diagnostics®); positive result of RPR test for syphilis 
was then confirmed by TPHA (solid phase immunochromatographic assay for the 
qualitative detection of antibodies of all isotypes (IgG, IgM, IgA) against Treponema 
pallidum (TP) by SD Bioline Syphillis 3.0 Multi by Standard Diagnostics, Inc®). 
Procedure 
All participants provided written informed consent and the study was approved 
by the ethical committee of the Faculty of Medicine at the University of Indonesia 
(protocol number: 731/UN2.F1/ETIK/2014).  People were first asked for serology 
testing and following collection of blood samples, the subjects filled in the 7 paper-
based questionnaires. Two field physicians and two Dutch psychology students 
were available during the data collection to explain the procedure and answer any 
questions when needed. No prison officers were present during the experiments. 
Data-analysis
First, subscale scores and total scores were calculated for all questionnaires. For the 3 
impulsivity measurements this included 9 subscales (3 BIS-11, 4 BIS/BAS and 2 SPSRQ 
subscales). Two subscales were eventually not taken into account regarding further 
analysis, as they are not directly measuring impulsivity (BIS scale of the BIS/BAS and 
SPSRQ punishment scale; measuring tendencies towards inhibition behavior). Regarding 
risk behavior this included 3 total scores of the questionnaires, which we transformed 
into categorical variables according to established cut-off scores, dividing no/low from 
high risk behaviors (alcohol-: AUDIT > 7, drugs-: DAST > 2, and sex-related: SRB > 0). 
Next, to retrieve a general view from the research population, differences in 
demographic variables (age, education, occupation, marital status, committed 
crime) and infection rates were analyzed for the total sample and specified per risk 
behavior category. Kruskal-Wallis analysis of variance (ANOVA) was used for the 
continuous variable age and Chi-square tests for the other 4 categorical variables.
Furthermore, to test our hypotheses, we used binary logistic regressions. First we 
used 3 regressions to examine the associations between the various aspects of 
impulsivity and the 3 forms of risky behavior (path a in Figure 1). These impulsivity 
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variables were tested for multicollinearity. Moreover, age and education were 
included in the model, because risk behavior has shown to be associated with 
these two factors (Steinberg et al., 2008). Another regression analysis was used to 
examine the associations between risky behaviors and infectious diseases (path b 
in Figure 1). In addition, the associations between different forms of risk behavior 
and having an infection disease (computed by making a sum score of the infection 
rates) were tested (path c in Figure 1). Finally, a regression analysis was performed 
to predict infectious diseases, by using the indices of impulsivity together with the 
measures of risk behavior as mediators (path c’ in Figure 1).  
RESULTS  
Descriptive statistics 
Participants who showed risky behavior (alcohol-, drugs- or sex-related) were younger 
(F(1, 214) = 5.768, p = .017) and did go to prison for a drug-related crime more often 
(χ2(1) = 23.562, p < .001) compared to those without showing risky behavior. The other 
demographic variables did not differ between participants with and without risky 
behavior (p > .069). Looking at the total sample of participants, infectious diseases 
were diagnosed in 38 (17.8%) subjects, including HIV (3.7%), syphilis (7.0%), HBV 
(3.3%), and HCV (2.3%). Detailed study characteristics are shown in Table 1.  
Associations between impulsivity and risky behavior
First, there was no noteworthy multicollinearity between predictor variables (VIF 
< 1.632). Furthermore, the first regression analysis showed a significant prediction 
model for problematic alcohol use, based on impulsivity measures (χ2(9) = 32.092, 
p < .001, Nagelkerke R2 = .204), with an overall correct prediction of 76.2%. The 
Wald criterion demonstrated that BIS-Motor impulsivity (p = .024) and age (p = 
.004) significantly contributing to the prediction. 
Similarly, impulsivity reliably predicted problematic drug use (χ2(9) = 24.351, p = 
.004, Nagelkerke R2 = .152). Overall prediction of the models’ success was 70.6% 
and the SPSRQ-Reward significantly contributed to the prediction (p = .016). 
Finally, impulsivity measures could also predict sexual risk behavior (χ2(9) = 
25.634, p = .002, Nagelkerke R2 = .151). The overall prediction of success was 
67.3%. Furthermore, BIS-Attentional  (p = .025) and BAS-Drive (p = .015) made a 
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significant contribution to the prediction. More detailed information about these 
variables and differences between the means, is shown in Table 2.
Mediation of impulsivity on risk behavior related infections by risk behavior
Another regression analysis showed a significant prediction model for infectious 
diseases based on the impulsivity measures (χ2(9) = 19.936, p = .018, Nagelkerke 
R2 = .146). The overall prediction of success was 83.6%. According to the Wald 
criterion, BIS-Motor and BAS-drive impulsivity significantly contributed to the 
prediction (respectively p = .024, p = .041). When adding risk behavior as a 
mediator, the model became less significant (χ2(12) = 23.716, p = .022, Nagelkerke 
R2 = .173), while the total prediction of success increased to 84.6%. However, the 
model of risk behavior predicting infectious diseases seemed to be non-significant 
(χ2(3) = 4.197, p = .241, Nagelkerke R2 = .032), so a mediating effect could not be 
confirmed. The model is shown in Figure 1. 
CONCLUSION AND DISCUSSION 
Our findings show that different forms of impulsivity can predict the presence 
of risk behavior and infectious diseases among female prisoners in Indonesia. 
More specifically, we examined different forms of impulsivity: cognitive, motor, 
lifestyle and reward-related, in combination with the effect of age and education 
(correlated with risk behavior). The data showed that age and motor impulsivity 
can predict alcohol-related risk behavior. Furthermore, drug-related risk behavior 
can be predicted by age and reward impulsivity. Cognitive and lifestyle impulsivity 
can predict sex-related risk behavior. Finally, 3 different forms of impulsivity 
seemed to be relevant in a model to predict infectious diseases, namely motor, 
reward and lifestyle impulsivity. Due to a non-significant relationship between 
risky behavior and infectious diseases, there was no mediation effect shown. To 
summarize these different predictive models, we can conclude that the younger, 
the more sensitive to reward, and the less able to inhibit cognitive and physical 
impulses, the more likely someone is to show risky behavior. 
Previous research among females also reported an association between motor 
impulsiveness and alcohol use (Fu, Ko, Wu, Cherng, & Cheng, 2007) and a 
moderating effect of impulsivity on the relationship between gender and 
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substance use (Stoltenberg, Batien, & Birgenheir, 2008). Later, it was also shown 
that more substance abuse was associated with higher reward seeking behavior 
(Leasure & Neighbors, 2014). Regarding drug use, previous studies stated that 
female drug users show higher motor impulsiveness compared to drug-using and 
none-using males (Perry et al., 2013). Our findings confirmed this statement by 
showing that impulsivity, namely reward sensitivity, is indeed associated with 
drug use among female inmates. Neuroscience research has shown that drug use 
is in some way related to dysfunction of the reward system (Alguacil & Gonzalez-
Martin, 2015), which can probably explain some part of the relationship. Looking at 
sexual risk behavior, it shows analogous results with previous reports mentioning an 
association between more lifestyle/fun seeking behavior among female adolescents, 
resulting in more sexually transmitted infections such as HIV (Sales et al., 2013). 
Furthermore, the results show a relationship between impulsivity and the 
presence of infectious diseases. Motor impulsivity (acting without thinking,) and 
reward sensitivity seem to be predictive factors in this relationship, which seems 
to be self-evident among female inmates due to the character of a life in prison. 
Inmates can e.g. have financial problems and/or make impulsive considerations 
which are relevant in the recent moment (Amoo et al., 2015; Sanbonmatsu, 
Strayer, Medeiros-Ward, & Watson, 2013; Winters, Botzet, Fahnhorst, Baumel, & 
Lee, 2009). Likewise, looking at reward impulsivity, short-term gains can be more 
important  to prisoners compared to long-term gains (Pisani, 2010). 
Looking at the limitations of this study, we wondered if combining the presence of 
HIV, HBV, HCV and syphilis infections into one variable might be unspecific, due to 
the many possible ways of disease transmission. On the other hand, the numbers 
of infections were perhaps too low for the prepared analyses. Especially, when 
the ways of transmission are very diverse, it is difficult to diffuse a low number 
into subgroups. Some subjects had a history of injecting drug use (IDUs); the most 
frequent route for HIV, HCV or HBV transmission, while others reported a history 
of being commercial sex workers or having had multiple partners, which may have 
resulted in them acquiring or spreading HIV, HBV or Syphilis. A large case control 
study, comparing people with a specific infection with healthy control participants, 
would provide more information about the relationship between impulsivity, risk 
behaviors and the presence of infectious diseases.  
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However, currently there is a growing interest to find behavioral background to 
explain clinical diseases, in particular infectious diseases, to further shape preventive 
measures. Our study contributes to some findings from previous reports and we have 
been able to demonstrate more specifically, that different aspects of impulsivity can 
have a predictive value to say something about amounts of risk behavior and infectious 
diseases. Previously, the relationship between substance use and risk behavior 
was mainly examined in studies concerning male participants and not concerning 
psychological factors such as impulsivity (Basu, Sharma, Gupta, Nebhinani, & Kumar, 
2015; Kogan, Cho, Barnum, & Brown, 2015). As epidemiological research has shown 
differences in risk behavior between genders, and emphasized women and prisoners 
as vulnerable populations for risk behavior related infections (Larney, Mathers, Poteat, 
Kamarulzaman, & Degenhardt, 2015; Pruss-Ustun et al., 2013; United Nations Office 
on Drugs and Crime, 2015), it is important that we examined risk behavior and its 
diffused correlates among female prisoners. Armed with this knowledge, it is almost 
self-evident that we have to pay more attention towards elements of impulsregulation, 
when developing infectious disease prevention programs.  
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Figure 1. Relationship between impulsivity and infectious diseases, mediated by risky 
behavior (R2 is reported for each model).
* p < .05
a In combination with age and education 
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ABSTRACT
Validated data regarding HIV-transmission in prisons in developing countries is 
scarce. We examined sexual and injecting drug use behavior and HIV and HCV 
transmission in an Indonesian narcotic prison during the implementation of an 
HIV prevention and treatment program during 2004-2007 when the Banceuy 
Narcotic Prison in Indonesia conducted an HIV transmission prevention program 
to provide 1) HIV education, 2) voluntary HIV testing and counseling, 3) condom 
supply, 4) prevention of rape and sexual violence, 5) antiretroviral treatment 
for HIV-positive prisoners and 6) methadone maintenance treatment. During a 
first survey that was conducted between 2007 and 2009, new prisoners entered 
Banceuy Narcotics Prison were voluntary tested for HIV and HCV-infection after 
written informed consent was obtained. Information regarding sexual and injecting 
risk behavior and physical status were also recorded at admission to the prison. 
Participants who tested negative for both HIV and HCV during the first survey were 
included in a second survey conducted during 2008-2011. During both surveys, 
data on mortality among HIV-seropositive patients were also recorded. All HIV-
seropositive participants receive treatment for HIV. HIV/AIDS-related deaths 
decreased: 43% in 2006, 18% in 2007, 9% in 2008 and 0% in 2009. No HIV and HCV 
seroconversion inside Banceuy Narcotics Prison were found after a median of 23 
months imprisonment (maximum follow-up: 38 months). Total of 484.8 person-
years observation was done. Participants reported HIV transmission risk-behavior 
in Banceuy Prison during the second survey was low. After implementation of HIV 
prevention and treatment program, no new HIV or HCV cases were detected and 
HIV-related mortality decreased.
Keywords: HIV, HCV, Transmission, Prison, Prevention, Treatment, Indonesia
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INTRODUCTION
The prevalences of Human Immunodeficiency Virus (HIV) and Hepatitis C virus 
(HCV) are often higher in prisons than in the general population due to a higher 
prevalence of those with a history of injecting drug use (Dolan et al, 2007). 
Continued injecting drug use and sexual risk behavior in prison may contribute 
to further transmission of HIV, HCV and other infections (Rotily et al, 2001; Boys 
et al, 2002; El Maerrawi and Carvalho, 2015). Testing for HIV of inmates on entry, 
periodically during incarceration, and before release, are recommended by the 
United States CDC (CDC, 2006); this testing could offer correctional institutions the 
opportunity to prevent and treat HIV and monitor prevalence and incidence of HIV 
infection in this population (Jurgens et al, 2011). Data regarding HIV transmission 
in prison is limited and primarily from developed countries (Horsburgh et al, 
1990; Mutter et al, 1994; Krebs and Simmons, 2002; CDC, 2006; Jafa et al, 2009; 
Jurgens et al, 2011). The largest study documented 88 seroconverters between 
1992 and 2005 among 73 prisons in Georgia, United States (CDC, 2006). Another 
study reported 2 seroconversions among 1,105 inmates in a single prison in 
Nevada (Horsburgh et al, 1990). There is indirect evidence of outbreaks and HIV 
transmission in prisons from different parts of the world (Wright et al, 1994; 
Weinbaum et al, 2005). Prisoners in low-income countries are at increased risk 
for becoming infected during incarceration, since HIV prevalence rates in prison 
are higher, there is overcrowding and sub-standard living conditions and less 
availability of HIV preventive and therapeutic services (Dolan et al, 2007; Angora 
et al, 2011; Jurgens et al, 2011). However, there is no direct evidence that supports 
this hypothesis. A study in Thailand in 1988 showed that 5% HIV monthly incidence 
among 1,091 injecting drug users (IDU) had occurred during imprisonment (Wright 
et al, 1994). A high prevalence of HCV among prisoners has been documented 
inside prisons of developed countries (Kim et al, 2013; Alvarez et al, 2014; Snow et 
al, 2014). The prevalences of HCV reported from several Australian prisons range 
from 21% to 58% with seroconversion rates being between 5 and 34 cases per 100 
person years during incarceration (Snow et al, 2014).
Prisons may create the circumstances that fuel HIV and HCV transmission. 
However, prisons may also offer interventions to reduce HIV and HCV transmission. 
An evidence-based HIV and HCV preventive program should include: 1) HIV/
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HCV education, 2) voluntary HIV/HCV testing and counseling, 3) condom supply, 4) 
prevention of rape and sexual violence, 5) treatment of HIV-positive prisoners and 6) a 
needle exchange and methadone maintenance program (Jurgens et al, 2009; Beckwith 
et al, 2010; Beyrer et al, 2010). Such activities can be established if there is commitment 
from prison authorities, endorsement of services by prison staff and prisoners, and 
collaboration with health care providers outside the prison (Nelwan et al, 2009). At risk 
populations outside the prison may be more difficult to access (Jurgens et al, 2009), but 
the at risk population in prison is easier to access and their treatment may be more cost-
effective (WHO, 2008; Siregar et al, 2011; Wammes et al, 2012).
The present study was carried out in Indonesia, which has one of the fastest 
growing HIV epidemics in Asia, with injecting drug use as the main factor driving 
the epidemic (Dolan et al, 2007). We have previously examined the prevalences 
and behavioral correlates with HIV, Hepatitis B (HBV) and HCV infections among 
prisoners in Banceuy Prison, which is the main narcotic penitentiary in West Java, 
Indonesia. In this prison, injecting opioid users are incarcerated along with non-
injecting cannabis users. We previously reported that among 639 all incoming 
prisoners that agreed to be included in the study and to be tested for HIV and 
hepatitis B/C, 18.0% reported a history of injecting drug use, 7.2% had HIV infection 
and 18.6% had HCV infection (Nelwan et al, 2010). Previous imprisonment was 
reported by 20% of these inmates whereby 95% of the prisoners also conveyed risky 
sexual behavior and 12% injecting drug use during previous incarceration (Nelwan 
et al, 2010). The purpose of the present study was to determine the prevalence 
of injecting drug use, sexual behavior and HIV and HCV infection status on entry 
and on release from prison. This study was conducted after an HIV prevention and 
treatment intervention was introduced at this prison. Prisoners who were HIV-
seronegative at time of entering the prison were interviewed, examined and tested 
for HIV and HCV infection before release. To the best of our knowledge, this is the 
first study of its kind from developing country.
MATERIALS AND METHODS
Setting 
This study was conducted in Banceuy Prison, Bandung, West Java, Indonesia. 
Bandung is the capital of West Java, with 43 million inhabitants (Statistics of Jawa 
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Barat Province, 2012). This prison was built for a maximum of 450 prisoners, but 
it contains about 1000 prisoners and every month 30-50 new prisoners arrive. 
Banceuy is a referral prison that receives prisoners who are sentenced to more 
than one year and are referred from other correctional facilities. Health care at 
the prison is provided in both outpatient and a small inpatient facility by general 
practitioners, dentists and three nurses. 
Comprehensive HIV activities
Since 2004 Banceuy Prison has collaborated with Padjadjaran University (UNPAD) 
Bandung and Rumah Sakit Hasan Sadikin (RSHS), the main academic referral 
hospital in West Java, to prevent, control and treat HIV infection among prisoners. 
The HIV control program described elsewhere (Nelwan et al, 2010) was conducted 
between 2004 and 2007 with the help of  psychologists and internists from UNPAD 
and RSHS, and included HIV education and training, HIV prevention, conseling, 
testing, and care for HIV/AIDS. Most of the prison staff have received training in the 
basics of HIV, such as its signs and sypmtoms, transmission, prevention and harm 
reduction. Paramedics were trained in voluntary counselling and testing (VCT) 
and addiction care, and the medical staff were trained in all aspects of HIV care, 
including treatment. All incoming prisoners were also educated in HIV. HIV VCT 
was introduced. Condoms were made available at the prison clinic. A psychologist 
visited the prison weekly and provided counseling for victims of rape and sexual 
violence. Harm reduction included training of health care workers in addiction care 
and provision conducting a methadone maintenance treatment (MMT) program. 
A needle exchange program was not conducted for safety reasons although 
studies indicate  such methods are effective and safe (Alvarez et al, 2014). At the 
prison bleaching agent distribution was provided. Antiretroviral treatment (ART) 
and treatment of opportunistic infections was introduced and provided by prison 
doctors, under weekly supervision from specialists from RSHS following national 
guidelines. The health facilities of the prison were upgraded. Severely ill prisoners 
were referred to RSHS. CD4 cell counts and other necessary diagnostic tests were 
performed at RSHS. All medical services were provided free of charge through 
a memorandum of understanding (MoU) between Banceuy Prison and RSHS/
UNPAD, a joint MoU between the Ministry of Law and Human Rights, Ministry 
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of Social Affairs and Ministry of Health; local and international organizations also 
collaborated: the funded program called Integrated Management for Prevention 
And Care and Treatment (IMPACT) of HIV among IDU in West Java, Indonesia was 
funded by the European Commision (EC). These were the main sources of funding 
for the HIV-related activities during 2006-2011 at the Banceuy Prison. This funding 
allowed temporary allocation of medical staff, to carry out activities related to 
the study. The health care workers were trained in all aspects of HIV and the 
ethical aspects of the study, such as confidentiality and voluntary  participation 
of subjects. One of the authors of this paper (E.N.) supervised all the activities of 
the present study to ensure confidentiality, the free will of the patients, and the 
laboratory samples were processed correctly. Laboratory results were given to the 
prisoners and treatment was initiated when indicated. Independent research staff 
safeguarded against interference from prison staff. Because of these activities, 
the Indonesian government appointed Banceuy Prison as a referral prison for 
comprehensive HIV care. Between August 2007 and January 2009, HIV testing 
was done in all incoming prisoners during routine medical screening on prison 
intake, unless inmates refused (opt-out). 
Study design and procedures
A cross-sectional survey was conducted, this included an interview and serological 
testing for HIV and HCV infection. A total of 871 inmates entered Banceuy 
Prison between August 2007 and January 2009, the first survey was performed 
among 76% of the new prisoners.  Two hundreds and nine inmates (24%) were 
excluded because they were transferred elsewhere before the survey was started 
(Nelwan et al, 2010). After written informed consent was given, a semi-structured 
interview using a questionnaire was conducted by the clinic doctor asking about 
related to risk behavior during previous imprisonments, including a history of 
intraprison injecting drugs, receiving a tattoo and risky sexual behavior. Informed 
consent for HIV and HCV testing was also obtained. Those who tested negative 
on both the HIV and HCV tests during the first survey were eligible for the second 
survey, which was conducted between May 2008 and March 2011; the survey was 
conducted among prisoners at least one month before release. The second survey 
asked about the same risks as the first survey along with symptoms of HIV and 
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other sexually transmitted diseases. Data from the first survey was compared with 
data from the second survey. Subjects who tested positive for HIV were treated 
with antiretroviral therapy (ART) for free and those leaving prison were informed 
about where to continue treatment.
Ethical approval for this study was obtained from the ethics committee of 
Padjadjaran University Bandung. 
Laboratory testing
HIV antibodies were measured using commercially available rapid tests 
(Determine HIV-1/2, Abbott Laboratories, Tokyo, Japan or SD HIV-1/2 3.0, 
Standard Diagnostics, Inc, Kyonggi-do, Korea); followed by commercial EIA 
methods for detecting HIV (Virolisa HIV 1/2, Index Union Diagnostics, Korea) 
or the electro-chemiluminescence immunoassay (ECLIA) method for detecting 
HIV (HIV combi, Roche Diagnostics, Mannheim, Germany) following Indonesian 
national guidelines. Anti-HCV antibodies were detected using ECLIA (Roche 
Diagnostics, Mannheim, Germany). External quality control for the HIV and HCV 
testing was done (National Serology Reference Laboratory, WHO collaborating 
center, Victoria, Australia) showing 100% accuracy. CD4 cell levels were measured 
using Facscount Flow Cytometry technology (BD Biosciences, Jakarta, Indonesia)
Data analysis
Data obtained from the questionnaires and laboratory results were entered in 
a database using a code for each study participant. Nominal and ordinal values 
were expressed as percentages, continuous data as mean (SD) if normally 
distributed or median (IQR) if not. Comparisons between groups were made 
using an X2 test for nominal and ordinal variables, t–test for normally distributed 
data and a nonparametric Mann–Whitney U test for non–normally distributed 
continuous variables. The HIV incidence was calculated  by comparing the first 
survey results with those of the second survey. The person-years at risk for HIV 
and HCV infection were calculated based on the total number exposed to risk and 
the mean duration of stay in prison. Data were analyzed using SPSS, version 18.0 
(SPSS) for Windows. 
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RESULTS
During the first survey, conducted between August 2007 and January 2009, 46 of 
the 639 prisoners examined (7.2%) were seropositive for HIV (Nelwan et al, 2010). 
All HIV positive prisoners were given free treatment and HIV/AIDS-related deaths 
decreased: 43% in 2006, 18% in 2007, 9% in 2008 and 0% in 2009.  Of the remaining 
593 prisoners who  were HIV negative during the first survey 309 (52%) could be 
re-evaluated during the second survey. The median length of incarceration among 
these subjects was 23 months (484.6 person-years). Of these 28, refused repeat 
HIV testing, leaving 281 to be included in the second survey in the study. Regarding 
HCV, 18.6% (118/635) were HCV-seropositive and 517 of the 635 prisoners tested 
(81.4%) were HCV-seronegative during the first survey. Of these 265 (51.2%) could be 
re-evaluated during the second survey, but 26 (9.8%) refused repeat HCV testing (Fig 
1). Comparing inmates who were re-tested for HIV and HCV with those who were not 
re-tested, no significant differences in age, educational level, marital status or history 
of injecting drug use were seen. Prisoners included in the second survey reported 
more risky sexual activities (10.5% vs. 5.4%, p=0.03) and more tattooing (51.5% vs. 
37.5%, p=0.01) during previous incarceration prior to being incarcerated at Banceuy 
Prison. Only 11 inmates had ever received methadone.
Risky behavior was more frequently reported for a previous incarceration than 
during the current incarceration at Banceuy Prison. Ninety-six percent of prisoners 
(96%) had a previous history of incarceration, with a median length of incarceration 
of 31 days (Table 1). Ten percent of study subjects reported injecting drug use, 
and 55% reported having a tattoo for ornamental purposes by another prisoner 
during a previous incarceration. Sexual contact during previous a incarceration 
was reported by 7.8% of incoming inmates for whom data were available (n=562). 
Most of these sexual encounters (75%) took place with a spouse on a conjugal 
visit; very few sexual encounters with other male inmates were reported (Table 
1). Only one prisoner (0.3%) reported a sexual encounter and one prisoner (0.3%) 
reported injecting drugs during incarceration at Banceuy Prison; however, other 
unsafe skin-penetrating activities did still occur (Table 2). 
Only 0.6% of prisoners reported an HIV-related health complaint prior to release 
from Banceuy Prison (Table 3), such as weight loss, prolonged fever, chronic 
diarrhea or chronic cough. Sixty-three percent of subjects had no health complaints 
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during incarceration and did not visit the clinic,  17.6%  visited the clinic once and 
19.4% visited more than once, usually for symptoms such as diarrhea, common cold 
or itching. These may be attributable to poor sanitary  living conditions in the prison. 
Symptoms of suggesting sexually transmitted diseases (STD) were reported by 2.9% 
of subjects. Thirty-seven prisoners were advised to follow up medically after release 
from prison. Repeat serological testing for HIV and HCV was done among 281 prisoners 
(91%);  9% refused repeat testing. No HIV or HCV seroconversions were found.
DISCUSSION
In recent years, prisons have been recognized as a key intervention site to address 
the HIV epidemic (Flanigan and Beckwith, 2011). Injecting drug use has been 
fuelling HIV epidemics in many parts of the world and imprisonment is a common 
and recurrent event for most Injecting Drug Users (IDUs) (Dolan et al, 2007). 
The WHO, UNODC and UNAIDS have published a technical guide for countries 
to set targets for universal access to HIV prevention, treatment and care of IDUs 
(WHO, 2009) which is increasingly being used as a framework for developing a 
comprehensive package for core public health interventions (Jurgens et al, 2009). 
There is good evidence that these interventions when implemented in prisons, 
are effective in reducing risk behaviors, preventing HIV infections, and providing 
essential care and treatment services for IDUs (Jurgens et al, 2009). Most 
evidence comes from studies from industrialized countries evaluating a specific 
intervention while data from a combination of interventions in prisons are rarely 
reported and do not include data regarding HIV transmission in prison. 
In our study we found a dramatic reduction in HIV-related deaths as the mortality 
rate dropped from 43% in 2006 to 0% in 2009 at Banceuy Narcotic Prison. No 
HIV or HCV seroconversions were seen among the 393 prisoners during the 
study period and reported risk behavior at this particular prison was  low. It 
appears likely the HIV prevention and treatment interventions at Banceuy Prison 
contributed to this result, although the transmission risk was limited since only 
12.4% reported injecting drug use as HIV transmission risk behavior. Transmission 
risk behavior was assessed during incarceration by history only and not accurately 
reflect actual behavior but the lack of seroconversions speaks for itself. Indonesia 
has one of the fastest growing HIV epidemics in Asia and an important factor is 
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IDU. IDU in Indonesia is illegal; many drug users are  incarcerated, often more than 
once (Nelwan et al, 2010). Data regarding the prevalence of IDU in Indonesian 
prisons is lacking; however, national and international newspapers and books have 
reported rampant conditions (Bonella, 2009). HIV prevention programs and harm 
reduction strategies, such as opioid substitution and needle exchange, are virtually 
lacking in most Indonesian prisons so there is a legitimate concern that prisons fuel 
the current HIV epidemic in Indonesia. In many low and middle income countries 
prisons are high-risk environments for HIV transmission (Dolan et al, 2007). The 
present study indicates risk behavior and HIV transmission can be reduced in prison 
and supports the need to implement evidence based and HIV prevention programs 
in prisons as part of a national HIV prevention AIDS program. (Jurgens et al, 2009).
The HIV program implemented at the Banceuy Narcotic Prison was part of a large 
scale, integrated, European Commission (EC) funded program on prevention, 
control and treatment of HIV among IDU in West Java, Indonesia. The knowledge, 
attitudes, and practices of prison staff were addressed repeatedly, and prisoners 
received intense counselling regarding risk behavior and HIV and from peer 
support groups. General health care was improved, HIV-treatment and care for 
opportunistic infections was introduced, and universal (voluntary) screening for 
incoming prisoners for HIV infection was established, using an opt-out approach. 
Previous studies have shown the favorable effects of opt-out HIV testing. The US CDC 
recommends regular HIV testing at intake and release (Kavasery et al, 2009a,b; CDC, 
2010). A needle exchange program was discussed with prison authorities but not 
allowed (Nelwan et al, 2009). A methadone maintenance program was instituted 
free of charge, with support from the UNODC and the Indonesian government. 
Interestingly, only 11 inmates used the methadon maintenance program.  This may 
be due to the fact that many IDUs in Indonesia are not continuously injecting but 
may be characterized as recreational drug users. For them, methadone may not be 
the best solution (Iskandar et al, 2010; Sarasvita et al, 2012). The total number of 
IDUs may not have been very much since only 12.4% reported this HIV transmission 
risk behavior. Substance use is not restricted to opioids. It can included other drugs 
for which MMT is not indicated. Our program was successfully implemented in 
an Indonesian narcotic prison and may be more cost-effective than conducting it 
outside a prison (Nelwan et al, 2010; Siregar et al, 2011). Treatment of HIV infections 
lowers the HIV viral load and HIV transmission, as seen in our study.
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It is not always easy to implement some strategies and services inside a prison, 
even if the prison authorities support the program. Prison authorities may be 
hesitant to dispense clean needles, even though there have been no reports 
of syringes being used as weapons in prisons with syringe exchange programs 
(Alvarez et al, 2014). Prisons lack the necessary skilled staff, infrastructure 
and budgets to implement preventive or therapeutic services, such as  opioid 
substitution, drug rehabilitation programs, HIV testing or HIV treatment. These 
services are therefore not widely provided, especially in low-resource settings 
(Larney et al, 2007; Afriandi et al, 2009; Wolfe et al, 2010). The HIV program 
implemented at Banceuy Prison was facilitated by an European Commission (EC) 
grant and may not have occurred without this funding. It is important to have 
sponsoring organizations finance interventions in prisons in low-income countries 
(Sharma and  Chatterjee, 2012). National HIV prevention and treatment programs 
should also provide funding for prisons as interventions in these settings since 
they are cost effective and the subjects have poor access to treatment. 
An important limitation of this study was the fact the situation inside Banceuy 
Narcotic Prison is not representative of other prisons in Indonesia. Generalizability 
to other prisons in Indonesia or Southeast Asia is limited since IDU prevalence 
and type may vary by location. We do not have comparison data about HIV/HCV 
transmission inside a prison without the effects of a comprehensive HIV program. 
For ethical reasons it would not be acceptable to study HIV/HCV transmission 
without HIV prevention or treatment strategies in place. All the elements of the 
comprehensive HIV program were implemented before the study was carried 
out. It is therefore not possible to evaluate which element was most effective. A 
considerable number of prisoners might not have been re-evaluated since they 
were released or transferred from  prison in very short notice. The reliability 
of the self-reported behaviors during imprisonment can be questioned, since 
prisoners may not want to disclose HIV transmission risk behaviors. The sample 
size and duration of our study may have been too limited to document HIV or HCV 
transmission. However, with a background HCV seroprevalence of 18%, we would 
expect to find HCV seroconversion if substantial risk behavior were present. 
In conclusion, after introduction of HIV-prevention and treatment interventions at a single 
prison in Indonesia, low risk-behavior and no HIV and HCV transmission was documented. 
Importantly, also a significant reduction in HIV-related mortality was reported.
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Table 1. Baseline characteristics of HIV-seronegative incoming prisoners
Total     Subjects
(n = 593)
Age in years  (IQR) 29 (25-36)
Educational level
      No education 
      Primary school education
      Higher education
Marital Status
      Not Married
      Married / divorced
History of injecting drug use
HCV seropositive
Previous incarceration
Risk behavior during previous imprisonment
      Injecting Drug Use 
      Receiving a tattoo 
      Drug usea
      Sexual contactb
      Sex with male partner
      Sex with visiting wife
      100% condom use
      Time in prison in days (IQR)
6.3%
54.9%
38.8%
37.9%
62.1%
12.4%
12.1%
96%
1.1%
55.2%
7.7%
7.8%
0.5%
5.5%
0.1%
31 (22-51)
aIncludes heroin, marijuana, amphetamines, benzodiazepines, other stimulants and 
alcohol use; history of ever using these drugs not just in prison. 
bPrisoners were allowed to have sex in private with their spouse for several hours. 
Data are missing for education, marital status (n=5), history of drug use (n=4), previous 
imprisonment (n=11), history of having a tattoo (n=13), risky sexual behavior (n=31).
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Table 2. Reported drug use and risk behavior during incarceration at Banceuy Prison
Total Subjects
(n = 309)
Reported Drug User
      Injecting Drug Use 
      Heroin Use
      Marijuana
      Amphetamine
      Benzodiazepine
      Other drugs*
      Alcohol
Sexual behavior
      Sexual contact
      100% condom use
      Pay for sex
      Selling sex
Skin penetration
      Tattoo
      Male genital paraphernalia
0.3%
0%
9.4%
1.6%
1.3%
1.7%
7.3%
0.3%
0.3%
0.3%
0.3%
7.0%
7.8%
Study subjects (309) were interviewed regarding their behavior in prison one month prior 
to planned release. 
*other drugs include dextromethorphan, ephedrine, hallucinogens (magic mushrooms) 
and other tranquilizer drugs (clozapine).
Data are missing for marijuana, amphetamine, benzodiazepine, other drugs, alcohol 
(n=20), tattoos (n=24), genital paraphernalia (n=23)
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Table 3. Health evaluation of prisoners prior to release from prison
Total Subjects
(n = 309)
Clinical signs and symptoms
      HIV related symptoms 1 month prior to releasea
      Symptoms suggesting a STDb
HIV/HCV counseling and testing
      HIV test during clinic visitc, (positive/tested)
      HIV test at time of release, (positive/tested)
      HCV test at time of release, (positive/tested)
0.6%
2.9%
0/8
0/281
0/239
aHIV related symptoms included weight loss >10% of body weight, chronic diarrhea, fever 
>1month, chronic cough, oral thrush.
bSTD (sexually transmitted disease) includes any clinical condition of genital erosion, ulcer, 
discharge or vesicle. 
cTested in prison either because of withdrawal symptoms during imprisonment, perceived 
risk because shared utilities for tattoo, had a recurrent STD or during hospitalization at a 
referral hospital. 
Fig 1. Flow diagram of study subjects. 
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Abstract
Purpose - Routine HIV screening of prisoners is generally recommended, but 
rarely implemented in low-resource settings. Targeted screening can be used as 
an alternative. Both strategies may provide an opportunity to start HIV treatment 
but no formal comparisons have been done of these two strategies. 
Design/methodology/approach - We compared yield and costs of routine and 
targeted screening in a narcotic prison in Indonesia. Routine HIV screening was 
done for all incoming prisoners from August 2007 - February 2009, after it was 
switched for budgetary reasons to targeted (‘opt-out’) HIV screening of inmates 
classified as people who inject drugs (PWIDs), and ‘opt-in’ HIV testing for all non-
PWIDs. 
Findings - During routine screening 662 inmates were included. All 115 PWIDs 
and 93.2 percent of non-PWIDs agreed to be tested, 37.4 percent  and 0.4 percent 
respectively were HIV-positive. During targeted screening (March 2009 – October 
2010), of 888 inmates who entered prison, 107 reported injecting drug use and 
were offered HIV testing, of whom 31 (29 percent) chose not to be tested and 
25.0 percent of those tested were HIV-positive. Of 781 non-PWIDs, 187 (24 
percent) came for testing (opt-in), and 2.1 percent were infected. During targeted 
screening fewer people admitted drug use (12.0 versus 17.4 percent). Routine 
screening yielded twice as many HIV-infected subjects (45 vs 23). The estimated 
cost per detected HIV infection was 338 USD for routine and 263 USD for targeted 
screening.
Originality/Value - In a resource limited setting like Indonesia, routine HIV 
screening in prison is feasible and more effective than targeted screening, which 
may be stigmatizing. HIV infections that remain unrecognized can fuel ongoing 
transmission in prison and lead to unnecessary disease progression and deaths. 
Keywords HIV, Prison, Screening, Prevention, Effectiveness, Indonesia 
Paper type Research paper
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Introduction
Prisons have been neglected in the response to the global HIV epidemic (Beyrer 
et al., 2010; Jurgens et al., 2011), even though HIV prevalence rates in prisons are 
generally higher compared to the general population due to an over-representation 
of injecting drug users in prisons (Nelwan et al., 2010). Inside prison, people who 
inject drugs (PWIDs) usually have limited access to care (Centers for Disease 
Control and Prevention, 2006; Nelwan et al., 2009; Van Hest and Story, 2009; 
United Nations Office on Drugs and Crime et al., 2009; Strathdee et al., 2012), while 
high-risk behavior such as injecting drug and needle sharing between inmates 
inside prison is common (Culbert et al., 2015). Prisons may therefore provide 
a good opportunity to screen for HIV and initiate combination antiretroviral 
treatment (ART) (Nelwan et al., 2009). Hence, it is often recommended to screen 
all prisoners for HIV infection (Beckwith et al., 2010), or – as the WHO states – at 
least provide easy access to voluntary testing (United Nations Office on Drugs and 
Crime et al., 2009). 
Routine HIV testing in a prison setting was found to be cost-effective in the USA 
(Paltiel et al., 2005). Also for Indonesia, where the present study was conducted, 
the unit cost of counseling and testing in prisons was lower compared to other 
settings such as hospital-based clinics or STI/HIV community clinics, while 
enrollment rates in HIV care were higher (Siregar et al., 2011). Still, prisons in many 
countries lack the necessary resources and staff to implement routine screening 
for HIV infection. Furthermore, prisoners that are found HIV-seropositive should 
have access to treatment and care as well, which even in high-income countries 
like the USA often is a challenge (Hammet et al., 2007). It should be noted however 
that ART may be deferred – possibly even until after release - if HIV is diagnosed 
earlier when CD4 counts are relatively preserved, as was recently shown in the 
USA. (de Voux et al., 2012). Finally, for a country like Indonesia, sustainability 
of services for HIV is an issue with routine testing, as they often rely on donor 
funding or involvement of non-governmental organizations (NGOs) (Nelwan et 
al., 2009; Siregar et al., 2011). 
If resources are limited, prisons can opt for targeted screening of those prisoners 
with the highest presumed risk. This probably leads to lower case detection, 
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as was shown for symptom based for chlamydia and gonorrhea, both of which 
often occur asymptomatically, similar to HIV infection (Broad et al., 2009). On 
the other hand, for many prisons in Indonesia, like elsewhere, the capacity to 
perform routine screening is simply lacking. Except for Papua, Indonesia has a 
concentrated HIV epidemic strongly driven by injecting drug use. Drug use is 
illegal in Indonesia. Between 2002 and 2009 the number of inmates convicted 
for drug related offences increased fivefold accounting for 26 percent of people 
imprisoned (Directorat of Corrections Ministry of Justice and Human Rights, 
2010a). A survey in 2009 found an overall HIV prevalence rate among prisoners of 
3.6 percent, compared to an estimated sero-prevalence rate of 0.2 percent in the 
general population in Indonesia at that time (Directorat of Corrections Ministry of 
Justice and Human Rights, 2010a). A sentinel survey involving 2000 prisoners in 
11 provinces in Indonesia in 2011 showed a similar HIV prevalence of 3 percent 
(Indonesia Ministry of Health, 2011), while a higher prevalence of 7.2 percent was 
found among 625 unselected incoming prisoners in a narcotic prison in West Java, 
specifically appointed for individuals convicted for drug-related offences (Nelwan 
et al., 2010). In 2009 this latter prison changed from routine to targeted screening 
for budgetary reasons. 
While many other studies have described testing strategies in correctional 
settings (Zaller et al., 2007; Kavasery et al., 2009a, b; Beckwith et al., 2011, 2012), 
none have systematically compared two distinct testing strategies in terms of 
feasibility, acceptance, yield, and cost-effectiveness, and none have been done in 
low-resource settings.  
The change from routine to targeted screening in this Indonesian prison allowed us 
to evaluate how this policy change affected HIV case detection rates, expenditures 
and access to treatment.
Methodology
The study was carried out in Banceuy prison, which in 2003 was appointed 
by the Indonesian government as a “narcotic prison” for West Java, aimed for 
serving individuals convicted for drug-related offences. Banceuy prison often 
accommodates more than 1000 inmates although its official capacity is 450 
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prisoners. As referral prison, Banceuy receives about 30-50 inmates every month 
from detention centers, where individuals wait for their trial, and most serve 
sentences for more than one year. The prison contained a female section that was 
stepwise abolished between August 2007 and March 2008. For the present study, 
covering the period between August 2007 and October 2010, only male prisoners 
were included. Health care, including HIV treatment, is provided by an outpatient 
clinic and a small inpatient facility by one general practitioner, two dentists and 
three nurses, in close collaboration with medical specialists of the Hasan Sadikin 
Hospital in Bandung, the main tertiary referral hospital for West Java. 
In August 2007, routine (‘opt-out’) screening for HIV was initiated as part of a 
European Commission (EC) funded program called IMPACT aimed at prevention 
and treatment of HIV in the context of injecting drug use in West Java, Indonesia. 
IMPACT supported medical staff, medical and laboratory supplies in the prison 
and interventions were scientifically evaluated. From August 2007 to January 
2009, the prevalence of HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) 
was determined among all incoming prisoners; all inmates were registered and 
medically examined within one day after arrival (Nelwan et al., 2010). During 
registration, inmates were interviewed about personal characteristics and legal 
status. A medical examination was done including a brief history and physical 
examination. All incoming prisoners were referred to the prison clinic, the 
symptomatic ones immediately, those without symptoms within three months. 
In the clinic, prisoners were informed about the study and counselled about HIV. 
Experienced counsellors asked for informed consent to collect medical information 
and to test for HIV, HBV and HCV. If consent was given, an extensive medical 
history, physical examination and blood taking followed. Information about socio-
demographic data, medical history, physical status, risk behaviour and knowledge 
related to HIV infection was recorded using a structured questionnaire. 
In March 2009, routine screening for HIV was changed to targeted screening for 
budgetary reasons. Prisoners were registered and medically examined within one 
day after admission. During the medical check-up, all inmates were asked if they 
had ever injected drugs and examined for needle track changes or other signs 
of injecting drug use. An opt-out approach to Provider Initiated HIV Testing and 
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Counseling (PITC) was applied to all inmates with a history or signs of injecting 
drug use. These inmates were classified as “PWIDs”. Procedures were identical 
as described for routine screening, only that referral to the prison clinic was done 
within two weeks and serological screening was limited to HIV as no treatment 
options were available for HCV. In addition, specific information on signs or 
symptoms of HIV/AIDS or TB were collected. Besides targeted screening of 
individuals classified as PWIDs, an opt-in approach to Voluntary Counseling and 
Testing (VCT) in the prison was offered to all other prisoners, classified as “non-
PWIDs” entering Banceuy. Both during the period of routine (August 2007 – Feb 
2009) and targeted screening (March 2009 – October 2010), prisoners were asked 
about their HIV status, but none reported being HIV-positive or taking ART. For 
any prisoner found HIV-positive, the counselor arranged referral to the medical 
doctor for care, support and treatment as needed. All HIV-infected prisoners 
received CD4-cell testing and ART if indicated. There were no individuals who 
entered Banceuy prison twice during the study period 
Ethical Considerations and Responsibility
Ethical clearance for systematic and prospective data collection and analysis 
during both screening periods was obtained from the Ethical Committee of the 
Padjadjaran University Bandung (UNPAD) and the Research Ethics Committee of 
the Royal Tropical Institute, Amsterdam, the Netherlands. HIV counseling and 
testing was done by trained personnel in close collaboration with psychologists 
from UNPAD. All testing was voluntary, free of charge and confidential. After 
informed consent was obtained from the prisoners, data was collected in the prison 
clinic. The confidentiality of the subjects was assured and strictly maintained. 
Laboratory testing 
HIV antibodies were measured using commercially available rapid tests (Determine HIV-
1/2, Abbott Laboratories, Tokyo, Japan) or (SD HIV-1/2 3.0, Standard Diagnostics, Inc, 
Kyonggi-do, Korea); followed by commercial EIA methods (Virolisa HIV 1/2, Index Union 
Diagnostics, Korea) and ECLIA methods (HIV combi, Roche Diagnostics, Mannhein, 
Germany). External quality control of HIV testing was done (National Serology Reference 
Laboratory, WHO Collaborating Centre, Victoria, Australia) showing a 100% accuracy. 
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Estimation of the screening costs
To determine costs of screening, we used the unit cost of 23 USD for HIV testing 
from the health provider’s perspective as determined in a recent health-economic 
study in the same prison (Siregar et al., 2011). The total cost during routine or 
targeted screening was calculated by multiplying the total number of inmates 
tested by the unit cost of 23 USD. To compare the cost per individual diagnosed 
with HIV infection using routine or targeted screening, the total costs of testing was 
divided by the number of prisoners with a positive test for each period separately. 
Statistical Analysis
Nominal and ordinal values were expressed as percentages, continuous data were 
expressed as mean (SD) if normally distributed. Comparisons between groups 
were made using X2  test for nominal and ordinal variables, t-test for normally 
distributed and non parametric Mann-Whitney U test for non normally distributed 
continuous variables. Data were analyzed using SPSS 18.0 (SPSS) for Windows.
Findings 
Number of prisoners tested and HIV prevalence 
During the period of routine screening, 871 inmates entered Banceuy prison; 209 
inmates (24.0 percent) were excluded from analysis because they were transferred 
elsewhere before PITC could be implemented. The remaining 662 inmates were 
offered HIV testing through PICT as an opt-out approach, of whom 37 (5.6 percent) 
declined testing, 15 were afraid for venapuncture, nine were not ready to know 
their HIV status, eight ‘felt healthy’, and five gave no reason. From 625 tested, 45 
prisoners (7.2 percent; 95 percent CI 5.2 – 9.2) were found HIV positive (Figure 1). 
During the targeted screening period, 888 inmates entered Banceuy prison. They 
had a similar gender (100 percent male), the average age of 31.1 to 31.9 years 
during routine screening, and similar educational level, classified as “high school 
and above” in 38.6 percent of prisoners during targeted and 38.2 percent during 
routine screening. From 888 prisoners, 107 (12.0 percent) were classified as PWIDs 
and referred to the prison clinic for PICT. HIV testing was declined by 31 prisoners 
(29 percent) for several reasons: unreadiness to know the HIV status; refusal to 
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come to the clinic; detention in high-security block; came to the clinic more than 
three months after intake. Nineteen of the remaining 76 (25 percent; 95 percent 
CI 15.3 – 34.7) were found HIV positive. The prisoners who denied current or 
previous injecting drug use during intake (n=781) were considered at low HIV risk 
and were offered to come to the prison clinic for counseling and testing (“opt-in”). 
From this group 189 (24.2 percent) came to the clinic for fear they might be at 
risk. Two declined testing and ultimately four of 187 (2.1 percent; 95 percent CI 
0.04 – 4.2) were found HIV positive (Figure 1). During targeted screening a total of 
23 out of 263 prisoners who were screened were tested HIV-positive (8.7 percent; 
95 percent CI 5.3 – 12.1). 
  
Figure 1. Flowchart of incoming inmates during routine and targeted screening.
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Self-reported injecting drug use in relation to HIV screening and its results
Self-reported injecting drug use was strongly associated with HIV seropositivity. 
During routine screening, 115 (17.4 percent) inmates reported a history of injecting 
drug use and 37.4 percent of this group were HIV-positive, vs 0.4 percent in the 
non-PWIDs group (Table 1). During targeted screening period, 107 (12.0 percent) 
of inmates were classified as PWIDs and 25.0 percent of this group tested were 
HIV-positive compared to 2 percent of those classified as non-PWIDs, who came 
later to the clinic for HIV test  (Table 1). 
Table 1. Characteristics of prisoners during routine and targeted screening according to PWIDs-status
Routine screening Targeted screening
Non-PWIDs
n=547
PWIDs
n=115
p Non- PWIDs
n=189
PWIDs
n=107
     p
Age
(mean years±SD)
31.5  ± 8.2 29.3± 5.7 0.07 32.1 ± 8.4 29.5± 5.8 0.001
Graduation high 
school or more
36.2% 50.0% 0.04 35.4% 45.3% 0.14
Length of previous 
imprisonment 
(mean months 
±SD)
9.8+5.2 8.9+5.9 0.09 10.3 ± 6.8 10.3 ± 6.0 0.87
Accepted HIV test 510 (93%) 115 (100%) 0.001 187 (99%) 76 (71%) <0.001
HIV-seropositive 2 (0.4%) 43 (37%) <0.001 4 (2.1%) 19 (25%) <0.001
HIV WHO stadium 
1&2
1 (50%) 35 (81%) 0.23 4 (100%) 9 (47%) 0.08
CD4 (mean ± SD) 439+270 273+165 0.04 346 ± 154 242 ± 216 0.38
Differences between routine to targeted screening in terms of yield and costs
The change from routine screening to targeted screening was associated with lower 
detection of HIV infection, and detection at a later stage of disease. During routine 
screening, 100 percent of PWID and 93 percent of inmates without a history of injecting 
drug use accepted HIV testing. During the period of targeted screening, only 71 percent 
of PWID and 24 percent of non-PWIDs were tested. Overall, 94 percent of all 662 
prisoners during the period of routine testing, versus 89 percent of 296 approached 
during the period of targeted screening agreed to be tested (p<0.001). During the period 
of routine screening, HIV infection was detected in 45 of 662 prisoners, compared to 23 
infections in 888 prisoners during the period of targeted screening. 
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No significant differences in CD4 cell counts were found between prisoners who 
tested positive during routine and targeted screening, but the number of HIV 
infected prisoners with an early clinical stadium was significantly higher during 
routine screening (Table 1). Lower CD4 cell counts were found among those 
prisoners classified as PWIDs during both testing periods (Table 1). 
Using the unit costs of 23 USD for delivering testing in Banceuy prison as 
determined previously (Siregar et al., 2011), the total costs amounted to an 
estimated 15,226 USD (662x23 USD) during routine screening, and 6,049 USD 
(263x23 USD) during targeted screening. Based on these figures, the estimated 
costs per HIV infection detected were 338 USD during routine screening and 263 
USD during targeted screening. 
Discussion
We evaluated two HIV screening strategies in a narcotic prison in Indonesia. 
During routine screening, the “routine” aspect was well accepted. All inmates 
reporting injecting drug use agreed to be tested, while only 6.8% percent of those 
that did not report injecting drug use refused testing. Unfortunately, due to delays 
in the process approximately one fourth of prisoners could not be approached for 
testing before transfer to other prisons or release. However, routine testing could only 
be implemented with external resources for staff and testing reagents. When these 
additional funds were no longer available, targeted screening of inmates with a history 
or signs of injecting drug use, as the most important risk factor, was implemented. 
It is unlikely that the lower rate of HIV diagnosis during the period of targeted 
screening was due to an overall decline in the rate of HIV infection in Indonesia, as 
epidemiological data suggest the opposite (Indonesia Ministry of Health, 2014). 
It may be due to a lower proportion of PWID among prisoners, or rather, due to a 
lower number of PWID who got tested. During the period of targeted screening, 
PWIDs were approached for HIV using PITC, but almost one in three from this 
group declined HIV testing. In addition, some prisoners may have falsely denied 
drug use, probably fearing stigma or discrimination, leading to misclassification 
(Harawa et al., 2009). Indeed, during this period only 12.0 percent of prisoners 
admitted ever having injected drugs, compared to 17.4 percent during the 
period of routine screening. Although this problem was anticipated and an opt-
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in approach was available for non-PWIDs, only 24.2 percent of this group came 
forward to be tested. Therefore, the effectiveness of targeted testing was less 
than 70%, but could even be lower if PWIDs incorrectly reported no injecting drug 
use. 
To increase the effectiveness of targeted screening, the proportion of inmates that 
falsely deny injecting drug use should be as low as possible. In our study 6 out of 
189 (3.2 percent) non-PWIDs inmates who came for VCT admitted having injected 
drugs. Secondly, the refusal rate among those considered at high risk should be 
low, and reasons for test-refusal should be explored. The medical intake and 
counseling should be non-judgemental and confidential; inmates belonging to the 
high-risk groups and particularly the HIV infected should not be stigmatized and 
discriminated. Indeed, targeted screening in prison based on self-reported drug use 
can be discriminatory and raise ethical concerns (Harawa et al., 2009). These issues 
should be continuously monitored and remedial action should quickly be taken for 
optimal effectiveness of targeted HIV screening. Apart from screening among those 
classified as PWIDs, an opt-in approach for testing for the self-reported non-PWIDs 
classified group remains important. Although the yield in terms of HIV infections 
detected in this group was relatively low (2.2 percent), it provides an opportunity to 
counsel prisoners who have a higher HIV risk than the general population. 
Like in many countries, Indonesian prisons have few resources for health services. 
Therefore, from the prison point of view, lower costs are an advantage of targeted 
screening. In our study only 29 percent of the budget was spent for the targeted 
screening compared to the required funds to test all 888 incoming inmates. The 
actual figure might be somewhat less favorable since unit costs per test will be 
lower if large numbers of prisoners are tested. Furthermore, the costs related 
to undetected HIV infections were not calculated; during the period of routine 
screening twice as many HIV-infected cases were detected in a smaller number 
of prisoners. Inmates with unrecognized HIV infection may develop opportunistic 
infections and other complications that need treatment and hospitalization. 
In addition, those with HIV infection who are not aware of their infection are 
approximately three times more likely to transmit HIV than inmates who are 
aware of their infection (Marks et al., 2006), causing more morbidity and need 
for treatment. Also, if HIV infection leads to start of ART, the ‘prison viral load’ will 
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go down, lowering the risk of HIV inside prison (Castel et al., 2012). Therefore, 
unrecognised HIV-infection progressing to AIDS and transmitted to others during 
or after imprisonment carries a very high cost for the Indonesian society, and 
as such routine testing in prison is probably extremely cost-effective. It should 
be noted that costs for point-of-care tests have recently come down, further 
improving the cost-effectiveness of routine testing.
Our experience and that of others shows that HIV testing and care during 
imprisonment can be successful if implemented in a proper way, with the prisoners 
right to refuse testing, strict confidentiality, and good access to specialized care 
and support. Data from the USA indicate that about 75 percent of HIV-positive 
inmates initiate treatment while incarcerated and that effective HIV treatment 
in prisons has led to a 75 percent reduction in AIDS-related mortality (Nunn et 
al., 2010), a decline mirroring that of non-incarcerated populations (May et al., 
2006; Panos et al., 2008). In our study, since the introduction of HIV treatment 
and care inside Banceuy prison, all HIV-infected prisoners received CD4-cell 
testing and ART if indicated and among the first 25 patients initiated on ART in 
prison during routine testing, no one interrupted treatment and all but one had 
an undetectable HIV-RNA after six months of ART (Nelwan et al., 2010). Because 
of this, the AIDS-related case-fatality rate decreased from around 40 percent in 
2006 (before the HIV testing intervention) to 5 percent in 2010 (Banceuy Narcotic 
Prison, 2011). HIV treatment of PWIDs are often considered cumbersome, but 
we previously found a similar clinical and virological response to ART among that 
HIV patient with and without a history of injecting drug use (Wisaksana et al., 
2010). Also in other settings, it has been shown that up to 70 percent of prisoners 
and jail detainees can successfully achieve HIV viral suppression with ART during 
incarceration (Meyer et al., 2014a, b). 
Adequate resources for health in general and for HIV/AIDS in particular are a 
neglected priority in many prisons around the world. Due to limited resources, 
prisons are often faced with a lack of nurses and doctors to provide timely HIV 
screening, and scarce budgets and lack of health insurance for basic laboratory 
tests, radiological examination and medication including ART (Nelwan et al., 
2009). Such circumstances do not easily allow implementation of routine HIV 
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screening in prison. In Indonesia, some prisons have introduced routine screening 
that was interrupted when donor funds were reduced (Isa, 2011). The national action 
plan of AIDS provides a budget that is sufficient to counsel and test only 10 percent 
of inmates (Directorat of Corrections Ministry of Justice and Human Rights, 2010b). 
Prisons in other low and middle-income countries might face a similar situation, and 
even in the USA not all prisons could continue to apply routine screening (Walensky et 
al., 2005). Screening inmates during intake provides an opportunity for early detection 
and treatment, which may prevent further HIV transmission inside prison.
This study suffers from the limitations of an observational study conducted 
in a single prison, which limit the generalizability of its findings. In addition, 
misclassification of prisoners as non-PWIDs may have impacted our estimates 
of the effectiveness of targeted screening. Finally, the cost analysis in our study 
did not incorporate the implications of screening in terms of treatment, and 
implication in terms of transmission and disease progression among missed cases. 
Mathematical modeling could help estimate the costs of the likely missed cases 
in targeted screening. Despite these limitations, our study provides evidence, 
particularly for prison authorities, on the importance of HIV testing, treatment 
and care for prison populations. This is in line with recommendations from 
UNODC/UNAIDS/WHO (United Nations Office on Drugs and Crime et al., 2009).
Conclusion
Routine HIV screening for inmates proved to be effective in this setting, but in case 
of limited resources, targeted screening may be used for those that self-report 
injecting drugs. In any case, HIV screening, treatment, care and support should 
be available in prison, particularly in narcotic prisons, to contribute to control the 
spread of HIV epidemic.
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Introduction
In many countries, higher rates of HIV infection are reported among prisoners 
compared to the general population.1 This is due to various reasons, including 
the over-representation of people who inject drugs (PWID) in prisons. Sharing 
of contaminated injecting equipment, but also unprotected sexual contact, 
possesses a high risk of transmission of HIV and outbreaks of HIV infection in 
prisons have been documented from several countries. Prisons offer unique 
opportunities to screen for HIV infection and to start antiretroviral treatment 
(ART).2-4 However, there are only limited data from low-income and medium-
income countries that have documented injecting drug use (IDU) and related HIV 
infection within prisons.5-8 Despite the high HIV transmission risk behavior inside 
prisons, access to harm reduction programs seem very limited, especially in many 
resource poor settings, although exact data are still sparse.9-12 All of the above also 
apply to Indonesian prisons; many PWID have a history of incarceration, and IDU 
is a main factor driving the epidemic.13 The combination of high HIV transmission 
risk behavior inside the prisons, lack of disease prevention programs and recurrent 
incarceration of prisoners (recidivism) is not only a threat for prisoners, but also 
potentially increases HIV transmission from prison to the general population in 
Indonesia.14,15 
Thesis summary
The present thesis describes different studies in two Indonesian prisons 
concentrating on HIV infection among prisoners, thereby focusing on three 
factors. First, we aimed to explore the barriers, opportunities and possible 
benefits as well as practical issues of delivering effective HIV-prevention and care 
in prison. Second, we determined the prevalence of HIV, hepatitis B and hepatitis 
C infection and related risk behavior of prisoners. Finally, we examined the effect 
of a comprehensive HIV prevention, treatment and care program in an Indonesian 
prison. A conceptual framework outlining important factors for HIV transmission 
among prisoners in Indonesia was used (see Figure 1). 
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Figure 1. Conceptual framework outlining important factors for HIV transmission among 
prisoners in Indonesia.
The first part of this thesis highlights challenges and opportunities regarding 
development of HIV care and prevention in prisons in Indonesia. Ideally, a prison 
provides comprehensive programs for HIV that includes voluntary counseling and 
testing, reduction of HIV transmission risk behavior programs, delivering of HIV 
treatment and provision of specialized care. However, the implementation of 
such measures may be difficult for several reasons. Firstly, a prison is not a health 
institution, which makes that prison face technical and budgetary constraints such 
as a limited number of staff, the unavailability of laboratory testing or radiological 
examination, and inadequate supply of medication. Secondly, poor sanitation 
and overcrowding in prisons in resource poor settings may contribute to HIV 
transmission and spread of other diseases like scabies, tuberculosis, and acute 
diarrhea, commonly found among inmates. The third problem which may further 
complicate HIV-prevention and care in prison is the stigma that is surrounding HIV/
AIDS among prison staff and prisoners. Knowledge, attitudes and beliefs among 
prison staff also needs to be considered since discrimination among that group 
may hamper adequate HIV-prevention efforts. All those challenges should be the 
responsibility for both government and private organizations. A good collaboration 
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between local or regional health care providers and prisons is a prerequisite to improve 
HIV care as specific knowledge and facilities may be too limited within prisons. Active 
support from the prison authorities is crucial and mandatory to implement and 
sustain any activity. In addition, the involvement of the prisoners is also essential since 
behavioral changes and compliance to medication are important determinants of 
the success of the HIV program. These barriers in providing clinical care inside prison 
were also highlighted in a recent review, showing that appropriate action might still 
be challenging even if problems have already been identified; innovative strategies to 
improve health outcomes for prisoner were recommended.16
The second part of this thesis focuses on the prevalence and risk behavior related 
to HIV and HBV, HCV infection inside prison. In Banceuy prison, West Java, Indonesia 
we screened 639 out of 679 incoming prisoners for HIV, HBV, and HCV infection. 
The results showed a seroprevalence of 7.2% (95% CI 5.2–9.2) for HIV, 5.8% 
(95% CI 3.9–7.6) for HBsAg and 18.6% (95% CI 15.5–21.6) for HCV among those 
prisoners (Chapter 3). Compared to the national prevalence rates of HIV and HCV, 
the incoming prisoners prevalence was much higher, i.e. (7.2% vs 0.4% for HIV and 
18.6% vs <4.0% for HCV). Chapter 3 and 4 also discuss the general characteristics 
and risk behavior according to HIV status. Among prisoners with a history of IDU, 
injecting behavior in prison was more common in HIV–positive than in HIV–negative 
individuals (70.6 vs. 29.4%, P<0.001). More specifically, Chapter 4 evaluates the role 
of impulsivity to predict risk behavior and infectious diseases. A cross sectional bio-
behavioral study conducted in the East Jakarta prison among female inmates found 
that different forms of impulsivity, such as cognitive, motor, lifestyle and reward 
related, in combination with age and education, correlated with risk behavior. 
Moreover, motor, reward and lifestyle impulsivity also relevant to the occurrence 
of HIV, hepatitis B and hepatitis C also syphilis as described in Chapter 4.  
The third part of the thesis addresses the effect of a comprehensive HIV 
prevention, treatment and care program in an Indonesian prison, which includes 
1) HIV education, 2) voluntary HIV testing and counseling, 3) condom supply, 
4) prevention of rape and sexual violence, 5) antiretroviral treatment for HIV-
positive prisoners and a 6) methadone maintenance treatment (Chapter 5). 
A study conducted in Banceuy Narcotic Prison, West Java, Indonesia showed a 
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dramatic reduction in HIV related deaths as the mortality rate dropped from 43% 
in 2006 to 0% in 2009. Furthermore, the study also showed that risky behavior 
among prisoners more frequently occurred at previous incarceration than during 
imprisonment at Banceuy prison. We conclude that HIV prevention, treatment 
and care interventions at the prisons can be effective in Indonesia to control the 
spreading of HIV and to reduce the HIV-related mortality. The sustainability of such 
HIV prevention, control and care program inside prison is however an important 
issues to be considered, as extra resources need to be allocated for these activities. 
This study provided evidence that has been discussed in the current review regarding 
the effectiveness of reducing infection inside prison, that will lead further in lower 
community based infections after release from the prison.17  A summary of the 
questions, approach and findings of this thesis is given in Table 1
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Table 1. Overview of research questions and findings of this thesis
Question Approach Finding
What are the challenges and 
opportunities regarding HIV care 
in Indonesian prisons? 
Case study of Indonesian 
prisons and HIV: part of problem 
and solution
Step wise approach 
needs to be taken; 
good general health 
care should be 
established, and 
access to ART should 
be available.
What is the prevalence of HIV, 
HBV and HCV in Indonesian 
prisons?
Sero-prevalence study of HIV, 
HBV, and HCV of the prisoners 
HIV and HCV highly 
prevalent among 
prisoners. 
What aspects of impulsivity relate 
to risky behaviors and  to infection 
with HIV, HBV, HCV and syphilis
Bio-behavioral cross-sectional 
study on the association of 
impulsivity and drug or alcohol 
abuse, as well as HIV, HBV, HCV 
and syphilis among female 
prisoners
Impulsivity can 
predict the presence 
of risk behavior and 
infectious diseases 
among female 
prisoners
What risk behavior is associated 
with HIV infection in prisoners?
Sero-status test questionnaire 
regarding medical history, 
physical status, and risk behavior 
relates to HIV infection
Injecting drug use 
the major risk 
factor related to HIV 
infection. 
How effective is the 
implementation of HIV care and 
treatment inside the prisons?
Sero-conversion survey 
including serology data and 
risk behavior before and during 
imprisonment. Recording 
of HIV-related mortality in 
Banceuy narcotic prison
A dramatic reduction 
in HIV related deaths 
as the mortality rate 
dropped from 43% in 
2006 to 0% in 2009. 
Risky behavior 
among prisoners 
more frequent 
during prior than 
during current 
incarceration.
General discussion
A study conducted in 2015 by the International Centre for Prison Studies found 
that more than 10 million people in the world were incarcerated.18 Furthermore, 
the study also noted that 197,630 people were incarcerated in Indonesia, ranking 
Indonesia on the ninth position of prison populations.19 As stated above, prisons 
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may be hotspots for certain infectious diseases, such as human immunodeficiency 
virus (HIV), hepatitis (hepatitis B and hepatitis C), and sexually transmitted diseases 
and WHO has therefore  formulated recommendations to contain these diseases 
among prisoners.20 The WHO policy addresses nine components, including: (1) 
provide political support by Government, policy makers and private organizations 
for establishing HIV care in prison (2) establish a legal basis and policy for HIV 
management in prisons, (3) implement appropriate standard of living inside 
prison, (4) organize local, national, or regional funds for HIV care in prisons, (5) 
provide standard and continuous general health services in prisons, (6) provide 
access to HIV care in prisons (test, counseling, drug addiction and HIV treatment 
are available, (7) train prison staff, (8) establish evidence-based services (9) 
establish international, national, and regional collaborations. Interestingly, most 
of the recommendations are not well implemented in Indonesian prisons because 
of insufficient support from local, regional or national health authorities and/or 
health care providers. Result is insufficient funding support and medical services, 
lack of knowledge among prisoners in Indonesia about HIV care and prevention 
programs, and lack of involvement of prison authorities in HIV programs.  
While Indonesia has a low HIV/AIDS prevalence in the general population, 80% 
of new HIV infections resulted from intravenous drug use (IDU) in the beginning 
of the epidemic.21,22 Until December 2013, West Java Province had 4131 officially 
recorded HIV/AIDS cases, with 2493 cases among people who injected drugs 
(60.35%).23 Drug use is illegal and drug-addicts have a great change to end up 
in prison, where HIV may continue spread. IMPACT was a 5-year (2007-2011) 
EU-funded program that aimed to prevent, control, and treat HIV among IDUs in 
West Java Community. IMPACT interventions were also done at Banceuy Prison 
in Bandung, which is the biggest of two drug prisons in West Java, incarcerating 
commonly more than 1000 inmates despite a capacity of only 450.  IMPACT facilitated 
the strengthening of existing services and build academic capacity in Bandung with 
technical assistance from European partners. Among all interventions, a theatre 
program was developed for the prison community.24 The IMPACT activities led to 
the establishment of the Bandung-based Centre of Excellence for HIV/AIDS and its 
Opportunistic Infections. IMPACT has been the only program in Indonesia integrating 
HIV/AIDS activities in hospital, community, and prison. 
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Females contribute to 2-9% of the total prison population of the world. The 
number of incarcerated women and girls has increased by 50% since the year 
2000 and this increase cannot be explained by population growth. Female 
prison population levels have also been raising much faster than male prison 
population levels.25 Indonesia, with the largest population in Asia after India and 
China ranks ninth in terms of prison population worldwide with 197,630 people 
incarcerated, of whom 5.5% are females.19,26 In the country with more than 250 
millions inhabitants, there are 421 prisons and detention centers with nine places 
accommodating women and children.27 A random survey in 2010 selecting 200 
female inmates from four prisons in Indonesia reported an HIV prevalence of 6% 
and syphilis of 8.5% among female prisoners.11 Most studies in prisons are done 
among males, therefore to have a better view regarding the risk behaviors on 
females inmates, a study was conducted in an Indonesian female prison. Among 
the female prisoners, sex workers and drug users are overrepresented and these 
groups are also at a great risk to acquire HIV infection.28-30  Drugs and sex are 
also the main HIV transmission risk behavior in males, although characteristics 
between males and females may differ.31 In this thesis we investigated in female 
prisoners whether and how impulsivity, risk behaviors and infectious diseases 
associate. Impulsivity is recognized as an important predisposition towards risky 
behaviors such as drug abuse.32 In chapter 4,  we showed that motor and reward-
related impulsivity are predictive for problematic alcohol use, reward sensitivity 
is furthermore predictive for problematic drug use and cognitive and lifestyle 
impulsivity for sexual-related risk behavior. Eventually, this motor, reward and 
lifestyle impulsivity also seem to predict the presence of infectious diseases. 
Our findings in females are unique, as previous reports on impulsivity and HIV 
transmission risk behavior were carried out in males only and do not consider the 
different aspects of impulsivity.33,34
Within this thesis, the prevalence of HIV, HBV, HCV and syphilis among Indonesian 
prisoners is described. Moreover, the study also reports factors that contribute 
to transmission risk behavior that may lead to HIV, and hepatitis B/C infection. 
Dolan et al. 2007 found the prevalence of HIV and other blood-borne infections 
is generally higher among prisoners in low and middle income countries than 
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in the general community.1 Similar to that, our study in Banceuy prison in West 
Java found that compared to the national prevalence rates of HIV and HCV, the 
incoming prisoners’ prevalence is higher than the national general prevalence, 
i.e. (7.2% vs 0.4% for HIV and 18.6% vs <4.0% for HCV). According to WHO 2005, 
IDU was found as the main factor driving the HIV epidemic in Indonesia whereby 
prevalence rates above 50% have been reported among IDUs, while very low 
rates (0.2%) were reported in the general population.35,36 Additionally, other blood-
borne infections such as hepatitis B and C (HCV) are also more common among IDUs 
compared to the general population.37-39 Our research among Indonesian prisoners 
reported similar findings; 37.6% of incoming prisoners who reported a history of
IDU were HIV–infected, compared to 0.4% of those who denied IDU (P<0.001). 
Another major focus of this thesis was to provide evidence on the implementation 
of HIV care by reducing transmission and slowing disease progression. We found 
no incident cases of HIV among prisoners who had stayed in Banceuy prison for at 
least 23 months. We also noted a significant reduction in mortality as a result of 
our implementation efforts. In a recent systematic review it was mentioned that 
it is difficult to determine new HIV infection inside prison because routine HIV test 
is rarely performed on admission, possibly leading to an overestimation of new 
infections as a result of transmission inside prison.10 Dolan recently stated in the 
Lancet that “ the few studies on incidence suggest that intraprison transmission is 
generally low except for large-scale outbreaks”.4 Our study in chapter 5 reported no 
HIV seroconversion of inmates inside Indonesian prison during a comprehensive 
HIV prevention, control and treatment program. Moreover, we also found that 
routine screening can be implemented inside Indonesian prison as the testing, 
like previous reports from the US,40  was highly accepted. It is important to secure 
confidentiality and to limit stigma, as these factors are important reasons to 
refuse to test for HIV.41,42 Also, the health benefit of getting tested may be unclear 
to prisoners, especially in the absence of ART. 
We have shown that providing ART for inmates inside Banceuy prison was 
highly successful, not only because HIV related mortality reduced to zero but 
also because all but one of the 25 inmates had an undetectable plasma HIV-
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RNA during 6 months follow-up time on ART (chapter 3).  Reduction of viral load 
within prisons is important as this may lower intraprison HIV transmission as 
many of the people who inject drugs (PWIDs) continue to inject while being in 
Indonesian prisons.43 However, the knowledge, attitude and perception related to 
ART utilization among inmates greatly varies between prisons. A recent study in 
two large prisons in Jakarta identified negative feelings of inmates that restricts 
the proper utilization of ART initiated inside Indonesian prisons.44 
In our study, routine screening by voluntary counseling and testing (VCT) or opt-
in resulted in lower uptake of HIV testing, and fewer cases diagnosed compared 
to provider initiated testing and counseling (PITC) or opt-out. This was similar to 
what has been reported in the Maryland prison in the US, comparing opt-in with 
mandatory HIV testing.42 In the UK, the routine opt-out testing in prison context for 
HIV and other blood borne virus infections was just introduced recently.10 
In conclusion, there are clear challenges in providing HIV care inside prisons, both 
in low-middle income countries as well as in high-income countries.  However, 
efforts have started in many countries, including in Indonesia. This thesis shows 
that Indonesian prisons should take part in programs that focus on prevention, 
control and treatment of HIV by collaborating with other institutions outside 
prisons such as universities and referral hospitals. Furthermore, these prisons 
may profit from national and international support organizations.
Future recommendations
Apart from the studies presented in this thesis, several other items still need to be 
addressed. First of all, effective harm reduction strategies should be implemented 
inside prison while considering the local context and regulations. Secondly, 
large scale implementation of HIV prevention, control and treatment programs 
in Indonesian prisons are recommended however the effectiveness of these 
programs and their sustainability need to be analyzed. Thirdly, follow-up programs 
need to be established for IDU inmates or prisoners that are HIV-infected and are 
released from prisons. Currently the risk seems high that these ex-inmates do not 
get the proper follow-up so HIV treatment and/or harm reduction interventions 
are nor continued. Finally, adequate financial resources should be allocated for 
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prison health, not only because inmates have the right to be treated but also to 
protect the general community against communicable diseases. Priority should 
be given to study the cost-benefit of these interventions 
This thesis focuses on HIV in prison. This is only one factor, and one possible starting 
point for better HIV control in Indonesia. While South and South East Asia overall 
has witnessed an average decline of new HIV infections of 8% between 2005 and 
2013, Indonesia witnessed a 48% increase, and a 427% increase in AIDS-deaths 
over this period.45 In 2014,  an estimated 620,000 people were living with HIV in 
Indonesia, of whom only 8% have access to treatment. Similarly, the coverage of 
HIV prevention interventions is generally very low: needle exchange programs 
for drug users only reaches 10% of those in need and only 9% of HIV-infected 
pregnant women receive PMTCT or ART. Clearly, much remains to be done to step 
up HIV control and care in Indonesia. This thesis indicates that prison programs 
should be an integrated part of such efforts, not only because they might be very 
effective but also because it pays respect to the prisoners’ rights.46 
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Dit proefschrift beschrijft verschillende studies die uitgevoerd zijn onder HIV-
geïnfecteerde gedetineerden in twee Indonesische gevangenissen. Allereerst hebben 
we gekeken naar de barrières, mogelijkheden tot optimalisatie dan wel verbetering, 
alsmede naar de praktische problemen bij het tot stand komen van effectieve HIV-
preventie en zorg. Aansluitend hierop hebben we de prevalentie van HIV, Hepatitis 
B en C en daaraan gerelateerd risico gedrag van gevangen in kaart gebracht. Tot 
slot hebben we het effect van een omvangrijk HIV-preventie, behandeling en zorg 
programma onderzocht binnen de muren van een Indonesische gevangenis. Een 
conceptueel kader waarin belangrijke factoren over HIV-transmissie uiteen zijn 
gezet werd gebruikt als voorlichtingsmateriaal (zie Figuur 1).
Figur 1. Conceptueel kader waarin belangrijke factoren over HIV-transmissie uiteen zijn.
Het eerste gedeelte van het proefschrift beschrijft de barrières van en de 
mogelijkheden tot optimalisatie  van de zorg voor HIV-geïnfecteerden en de 
preventie van HIV-infecties onder gedetineerde in Indonesië. Idealiter, bieden 
gevangenissen behalve uitgebreide zorg omtrent HIV aan, waaronder een HIV-
test, counseling en  voorlichting over HIV-transmissie en risicogedrag en HIV 
behandeling. ook de beschikbaarheid van gespecialiseerd zorg en de benodigde 
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medicamenten voor behandeling. Echter de implementatie van dergelijke maatregelen 
binnen de gevangenismuren is om verschillende redenen  moeizaam. Ten eerste, een 
gevangenis is geen zorginstelling. Dit maakt dat de gevangenis wordt geconfronteerd 
met technische en budgettaire beperkingen, zoals een beperkt aantal medewerkers, 
geen beschikking over laboratorium- of radiologisch onderzoek en een inadequate 
levering van medicatie. Op de tweede plaats, dragen slechte sanitaire voorzieningen, 
overbevolking van de gevangenissen mogelijk negatief bij aan de HIV-transmissie, 
alsmede aan de verspreiding van andere ziekten zoals scabiës, tuberculose en 
acute diarree. Het derde probleem dat de implementatie van HIV-preventie en zorg 
verder compliceert in de gevangenis, is het heersende stigma rond HIV/AIDS onder 
gevangenen en het personeel. Factoren als kennis, attitude en geloofsovertuigingen 
onder personeel moeten ook in beschouwing worden genomen daar deze de kans op 
succesvolle implementatie van HIV-preventie kunnen belemmeren. Al deze obstakels 
dan wel uitdagingen zouden onder de verantwoordelijkheid van de regering en 
particuliere organisatie moeten vallen. Omdat specifieke HIV kennis en faciliteiten 
vaak beperkt zijn in gevangenissen is een goede samenwerking tussen lokale en 
regionale zorgproviders en gevangenissen staf een voorwaarde om de HIV-zorg te 
verbeteren. Actieve steun van de gevangenisautoriteiten is cruciaal en noodzakelijk 
voor de implementatie van het programma. Bovendien is de betrokkenheid van 
de gevangenen zelf ook van essentieel belang, aangezien gedragsveranderingen 
en therapietrouwheid belangrijke determinanten zijn voor het succes van het HIV-
programma. Deze barrières in het verstrekken van medische zorg in de gevangenis 
werden ook benadrukt in een recent global review waaruit blijkt dat , ondanks dat de 
problemen/obstakels al geïdentificeerd zijn HIV preventie en zorg in gevangenissen 
nog steeds moeilijk is. Innovatieve strategieën zijn aan aanbevolen om de gezondheid 
van de gevangenen te verbeteren.  
Het tweede deel van dit proefschrift richt zich op de prevalentie van HIV, Hepatitis B en 
C, en het daaraan gerelateerd risicogedrag in de gevangenis. In de Banceuy gevangenis 
op West-Java, Indonesië, hebben we 639 van de 679 binnenkomende gevangenen 
gescreend op HIV, Hepatitis B en C. De resultaten toonden een seroprevalentie van 
7,2% (95% BI 5,2-9,2) voor HIV, 5,8 % (BI 3,9 - 7,6) voor HBsAG en 18,6% (95%BI 15,5-
21,6) voor HCV (Hoofdstuk 3). In vergelijking met de nationale prevalentie van HIV 
en HCV, is de prevalentie onder nieuwe gevangenen aanzienlijk hoger. Ter illustratie, 
onder nieuwe gevangen is de prevalentie van HIV 7,2%, op nationaal gebied is dit 
113
Proefschrift samenvatting
slechts 0,4%, voor HCV is dit respectievelijk 18,6% versus <4,0%. In hoofdstuk 3 en 4 
wordt op basis van de HIV-status de algemene karakteristieken en het risicogedrag 
besproken. Onder gedetineerden met een voorgeschiedenis van intraveneus 
drugs gebruik, was HIV seropositiviteit  vaker geassocieerd met drugsgebruik in de 
gevangenis:  70,6% versus 29,4% onder HIV-negatieven (p<0.001). In hoofdstuk 4 
wordt de rol van impulsiviteit geëvalueerd als voorspeller van risicogedrag en het 
optreden van infectieziekten. Een bio-gedragsmatige cross-sectionele studie onder 
vrouwelijke gedetineerden in de gevangenis van Oost-Jakarta toonde aan dat er 
verschillende vormen van impulsiviteit  te onderscheiden zijn. Deze zijn onder 
te verdelen in cognitieve, motorische, leefstijl en beloning gerelateerd, welke in 
combinatie met leeftijd en educatie geassocieerd zijn met risicogedrag. Tevens is 
gebleken dat de verschillende vormen van impulsiviteit, behoudens de cognitieve 
vorm, ook een rol spelen bij het voorkomen van HIV, Hepatitis B en C, en syfilis.
Het derde deel van het proefschrift richt zich op het effect van een alomvattend 
HIV-preventie programma in een Indonesische gevangenis. Aandachtspunten 
hierin zijn 1) HIV educatie, 2) vrijwillige HIV-testen en counseling, 3) levering van 
voorbehoedsmiddelen (o.a. condooms), 4) preventie van seksueel misbruik en 
geweld, 5) antiretrovirale behandeling voor HIV-positieve gedetineerden en 6) een 
onderhoudsbehandeling met methadon (hoofdstuk 5). Een studie uitgevoerd in de 
Banceuy Narcotica gevangenis op West-Java, Indonesië, liet een drastische reductie 
zien van de HIV-gerelateerde mortaliteit, deze daalde van 43% in 2006 tot 0% in 2009. 
Deze studie toonde tevens aan dat risicogedrag onder gevangenen vaker voorkomt 
als zij reeds eerder in een andere gevangenis hadden gezeten. Hieruit concluderen 
we dat het opgezette HIV-preventie programma in de gevangenissen van Indonesië 
doeltreffend kan zijn om verdere verspreiding van HIV te voorkomen en de HIV-
gerelateerde mortaliteit kan terugdringen. Duurzaamheid van dergelijke preventie 
programma’s binnen de gevangenismuren is echter een belangrijk probleem dat in 
beschouwing moet worden genomen. Dit is met name te wijten aan de extra middelen 
die beschikbaar gesteld moeten worden voor een dergelijke preventie programma. 
Deze studie heeft bewijs gegenereerd over de effectiviteit van interventies gericht op 
de reductie van HIV prevalentie gevangenissen,  welke zullen leiden tot een lagere 
community-based HIV transmissie na invrijheidsstelling. Een overzicht van de vragen, 
aanpak en de resultaten van dit proefschrift worden weergegeven in Tabel 1.
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Tabel 1.  Overzicht van de onderzoeksvragen en bevindingen van dit proefschrift.
Onderzoeksvraag Aanpak Bevindingen
Wat zijn de uitdagingen en 
mogelijkheden met betrekking 
tot HIV gerelateerde zorg in 
Indonesische gevangenissen? 
Bestuderen van HIV in 
Indonesische gevangenissen: 
een deel van het probleem en 
de oplossing
Stapsgewijze 
benadering: 
goede algemene 
gezondheidszorg moet 
worden bewerkstelligd 
en antiretrovirale 
midden moeten tot de 
beschikking zijn.
Wat is de prevalentie van 
HIV, Hepatitis B en C in de 
Indonesische gevangenissen? 
Seroprevalentie studie naar 
HIV, Hepatitis B en C onder 
gevangenen
HIV en Hepatitis C 
komen frequent voor 
onder gevangenen. 
Welk aspect van impulsiviteit is 
gerelateerd aan risicogedrag en 
infectie met HIV, Hepatitis B en 
C, en syfilis?
Bio-gedragsmatige 
dwarsdoorsnede studie naar 
de associatie van impulsiviteit 
en drugs of alcohol misbruik, 
alsmede HIV, Hepatitis B en 
C, en syfilis onder vrouwelijke 
gevangenen
Impulsiviteit is een 
voorspeller voor 
de aanwezigheid 
van risicogedrag en 
het optreden van 
infectieziekten onder 
vrouwelijke gevangenen
Welk risicogedrag is 
geassocieerd met HIV-infectie 
onder gevangenen?
Sero-status test 
vragenlijst over medische 
voorgeschiedenis, 
gezondheidstoestand en 
risicogedrag gerelateerd aan 
HIV infectie
Intraveneus 
drugsgebruik is de 
belangrijkste risicofactor 
voor HIV-infectie 
Hoe effectief is de implementatie 
van HIV-preventie programma in 
de gevangenis?
Sero-conversie vragenlijst, 
inclusief serologie gegevens 
en inventarisatie van 
risicogedrag, voor en na 
gevangenschap. Registratie 
van HIV-gerelateerde sterfte in 
Banceuy narcotica gevangenis.
Drastische vermindering 
van het aantal 
HIV-gerelateerde 
sterfgevallen, deze 
daalde van 43% in 
2006 naar 0% in 2009. 
Risicogedrag onder 
gevangenen werd 
vaker gezien bij een 
eerste gevangenschap 
dan bij de huidige 
gevangenschap.
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Tesis ini memaparkan dua penelitian yang memiliki tiga fokus utama di dua Lembaga 
Pemasyarakatan di Indonesia tentang infeksi HIV pada warga binaan pemasyarakatan. 
Fokus pertama adalah mengidentifikasi tantangan, peluang dan manfaat termasuk di 
dalamnya aspek praktis dalam memberikan pelayanan yang efektif untuk mencegah 
dan mengobati HIV di lembaga pemasyarakatan. Fokus kedua adalah menentukan 
prevalensi infeksi HIV, hepatitis B dan hepatitis C serta faktor risiko yang terkait dengan 
infeksi tersebut. Fokus berikutnya adalah mendapatkan efek atau pengaruh dari upaya 
komprehensif dari program pencegahan, tatalaksana dan pelayanan HIV di dalam 
lembaga pemasyarakatan. Kerangka kerja yang memperlihatkan faktor-faktor 
penting yang berperan dalam penularan HIV di dalam lembaga pemasyarakatan 
di Indonesia yang digunakan adalah sebagai berikut (lihat gambar 1)
Gambar 1. Kerangka konsep yang menjelaskan faktor-faktor yang mempengaruhi 
penyebaran HIV pada warga binaan di Indonesia.
Bagian pertama dari tesis ini memfokuskan pada tantangan, peluang dan manfaat 
dalam memberikan pelayanan HIV di dalam lembaga pemasyarakatan di Indonesia. 
Secara ideal, sebuah lembaga pemasyarakatan seyogyanya memberikan pelayanan 
komprehensif untuk HIV meliputi konseling dan tes secara sukarela, memiliki 
program untuk mengurangi perilaku berisiko terhadap transmisi HIV, memberikan 
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layanan pengobatan HIV dan layanan khusus terkait infeksi oportunistik pada HIV. 
Namun pada kenyataannya, implementasi untuk hal tersebut sulit dilakukan karena 
berbagai macam sebab. Alasan pertama adalah lembaga pemasyarakatan bukanlah 
suatu institusi kesehatan, sehingga didapatkan adanya kendala teknis dan biaya 
juga keterbatasan jumlah pemberi layanan, kurangnya fasilitas laboratorium atau 
pemeriksaan radiologi, serta terbatasnya suplai obat. Alasan kedua, kurang baiknya 
sanitasi dan kepadatan di dalam lembaga pemasyarakatan berkontribusi terhadap 
penularan dan penyebaran berbagai penyakit termasuk scabies, tuberkulosis, diare 
akut, yang banyak ditemukan di warga binaan pemasyarakatan. Alasan lain yang 
dapat membuat upaya pencegahan HIV dan pemberian layanan kesehatan menjadi 
lebih rumit adalah stigma terhadap penderita HIV/AIDS dari kalangan staf maupun 
di antara sesama warga binaan di dalam penjara. Pengetahuan, sikap dan keyakinan 
dari staf di dalam lembaga pemasyarakatan terhadap HIV harus menjadi perhatian 
karena adanya diskriminasi terhadap warga binaan yang terinfeksi HIV dapat 
menghalangi upaya pencegahan penularan HIV secara adekuat. Semua tantangan 
tersebut di atas harus menjadi tanggung jawab bersama pemerintah dan organisasi 
swasta. Kerjasama yang baik antara pemberi layanan kesehatan di tingkat lokal dan 
regional dengan lembaga pemasyarakatan merupakan kondisi awal yang harus 
dibuat untuk dapat meningkatkan layanan HIV karena pengetahuan dan fasilitas 
yang spesifik dibutuhkan untuk hal ini dan tidak dapat semuanya diupayakan di 
dalam penjara itu sendiri. Peran serta aktif dari pemangku kebijakan untuk lembaga 
pemasyarakatan sangat penting dan dibutuhkan untuk dapat menerapkan dan 
mempertahankan aktivitas yang dilakukan. Selain itu, peran aktif dari warga binaan 
pemasyarakatan juga penting karena perubahan pola perilaku dan kepatuhan 
dalam minum obat merupakan faktor yang menentukan keberhasilan pelaksanaan 
program HIV. Semua tantangan dalam memberikan layanan kesehatan di dalam 
penjara ini, juga menjadi perhatian dalam ulasan yang baru diterbitkan, di mana 
upaya yang tepat dan sesuai tetap menjadi tantangan walaupun masalah telah 
diidentifikasi; dibutuhkan strategi yang inovatif untuk dapat meningkatkan hasil 
layanan kesehatan bagi warga binaan pemasyarakatan.16
Bagian kedua dari tesis ini focus pada prevalensi dan perilaku berisiko terhadap 
infeksi HIV dan hepatitis B, hepatitis C di dalam lembaga pemasyarakatan. Di 
lembaga Pemasyarakatan Banceuy, Jawa Barat, Indonesia, kami melakukan skrining 
status HIV, Hepatitis B dan Hepatitis C pada sebanyak 639 orang warga binaan 
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dari total 679 orang warga binaan yang baru masuk. Di dapatkan seroprevalens 
HIV sebanyak 7,2% (95% IK 5,2-9,2), 5,8% (95% IK 3,9 – 7,6) untuk hepatitis B 
dengan HBsAg positif dan 18,6% (95% IK 15,5 – 21,6) untuk hepatitis C (Bab 3). 
Dibandingkan dengan prevalensi nasional kejadian infeksi HIV dan Hepatitis C, 
pada warga binaan yang baru masuk lembaga pemasyarakatan didapatkan angka 
yang jauh lebih tinggi (7,2% vs 0,4% untuk HIV dan 18,6 vs <4,0% untuk hepatitis 
C). Dalam Bab 3 dan 4 didiskusikan pula karakterisktik umum dan perilaku berisiko 
dihubungkan dengan status infeksi HIV. Pada warga binaan pemasyaratakan 
dengan riwayat penggunaan narkoba suntik, menyuntik di dalam penjara lebih 
banyak ditemukan pada kelompok dengan status HIV positif dibandingkan HIV 
negative (70,6% vs 29,4%, p<0,001). Lebih spesik, Bab 4 mengkaji tentang peran 
impulsivitas dalam memprediksi perilaku berisiko dan penyakit infeksi. Penelitian 
potong lintang tentang bio-perilaku di lembaga pemasyarakatan Jakarta Timur 
pada warga binaan wanita menemukan berbagai bentuk impulsivitas seperti 
kognisi, motor, gaya hidup dan penghargaan yang bila dikombinasi dengan usia dan 
pendidikan, berhubungan dengan perilaku berisiko. Ditambah lagi, penghargaan 
dan gaya hidup sangat berkaitan dengan munculnya infeksi HIV, hepatitis B dan C 
juga sifilis yang dipaparkan di Bab 4.
Bagian ketiga dari tesis ini memfokuskan pada efek dari layanan komprehensif, 
pengobatan dan layanan HIV di lembaga pemasyarakatan di Indonesia yang 
meliputi 1) pendidikan HIV 2) tes dan konseling HIV secara sukarela 3) penyediaan 
kondom 4) pencegahan kekerasan seksual dan perkosaan 5) pemberian terapi 
antiretroviral pada warga binaan pemasyaratakan dengan HIV positif dan 6) 
pengganti terapi rumatan metadon (Bab 5). Sebuah penelitian di penjara narkotik 
Banceuy, Jawa Barat, Indonesia mendapatkan penurunan dramatis pada kematian 
terkait infeksi HIV dari 43% ditahun 2016 menjadi 0% di tahun 2009. Lebih jauh 
dari itu, penelitian ini juga mendapatkan perilaku berisiko diantara warga binaan 
pemasyarakatan lebih banyak dilakukan pada saat sebelum di penjara di Banceuy. 
Kami simpulkan bahwa upaya pencegahan, pengobatan dan layanan HIV di dalam 
lembaga pemasyarakatan  dapat efektif dilakukan di Indonesia untuk mengontrol 
penyebaran HIV dan mengurangi kematian akibat HIV. Kesinambungan program 
pencegahan, kontrol dan layanan HIV di dalam penjara merupakan hal lain yang 
penting di pikirkan, karena dibutuhkan lebih banyak sumber daya untuk semua 
kegiatan tersebut. Penelitian ini memberikan bukti sebagaimana telah di bahas 
118
Ringkasan (Indonesian Summary)
dalam review terbaru mengenai efektivitas mengurangi kejadian infeksi di dalam 
lembaga pemasyarakatan, yang diharapkan dapat kemudian mengurangi transmisi 
ke komunitas setelah keluar dari penjara.17 Ringkasan pertanyaan penelitian, 
pendekatan untuk menjawab dan temuan dari tesis ini di paparkan dalam Tabel 1.
Tabel  1. Ikhtisar dari pertanyaan penelitian dan temuan dari tesis ini
Pertanyaan Pendekatan Temuan
Apa saja tantangan dan 
peluang  dari pelayanan HIV 
di penjara Indonesia? 
Studi kasus dari penjara di 
Indonesia dan HIV: bagian dari 
masalah dan solusi.
Pendekatan bertahap 
perlu diterapkan; 
Pelayanan kesehatan 
umum yang baik perlu 
dilaksanakan, dan 
tersedianya akses terapi 
anti retroviral.
Berapa prevalensi dari HIV, 
HBV, dan HCV di penjara 
Indonesia?
Studi sero-prevalensi dari  HIV, 
HBV, dan HCV pada warga 
binaan. 
Prevalensi HIV dan HCV 
ditemukan tinggi pada 
warga binaan. 
Aspek impulsivitas apa yang 
berhubungan dengan perilaku 
berisiko dan infeksi HIV, HBV, 
HCV, dan sifilis?
Studi potong-lintang bio-
perilaku tentang asosiasi 
dari impulsivitas dengan 
penyalahgunaan alkohol atau 
narkoba, serta HIV, HBV, HCV, 
dan sifilis pada warga binaan 
perempuan.
Impulsivitas dapat 
berperan sebagai 
prediktor dari adanya 
perilaku berisiko 
dan penyakit infeksi 
pada warga binaan 
perempuan.
Apa saja perilaku berisiko 
yang berkaitan dengan infeksi 
HIV pada warga binaan?
Kuisioner tes status serologis 
berkaitan dengan riwayat 
kesehatan, status fisik, 
dan perilaku berisiko yang 
berhubungan dengan infeksi 
HIV.
Penggunaan narkoba 
suntik merupakan faktor 
resiko utama terhadap 
infeksi HIV.  
Seberapa efektif 
implementasi pelayanan dan 
pengobatan HIV di dalam 
penjara?
Survei sero-konversi meliputi 
data serologis dan perilaku 
berisiko sebelum dan sesudah 
masa tahanan. Pencatatan 
mortalitas yang berkaitan 
dengan HIV di Penjara 
Narkotik Banceuy.
Penurunan dramatis dari 
kematian yang berkaitan 
dengan HIV seperti terlihat 
pada penurunan angka 
mortalitas dari 43% pada 
tahun 2006 menjadi 0% 
pada tahun 2009. 
Perilaku berisiko pada 
warga binaan ditemukan 
lebih sering pada saat 
sebelum dibandingkan 
pada saat menjalani masa 
tahanan.
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